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“Let us keep looking, in spite of everything. Let us keep 
searching. It is indeed the best method of finding, and 
perhaps, thanks to our efforts, the verdict we will give 
such a patient tomorrow will not be the same we must 
give this man today.” 
Charcot – 1889 
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 No effective therapies exist for the treatment of patients suffering from amyotrophic 
lateral sclerosis, a devastating neurodegenerative disease characterized by motor neuron loss, 
paralysis, and death on average 3 – 5 years after diagnosis. Although multiple promising 
candidates have emerged from preclinical experiments in disease models, failure rates of 
randomized control trials assessing efficacy in humans are over 95%, demonstrating a need to 
improve the translation of preclinical findings to human biology. In this dissertation, I present 
original work investigating amyotrophic lateral sclerosis caused by mutations in SOD1 
(ALS
SOD1
) for the successful translation of SOD1-targeting strategies into meaningful treatment 
options for patients. Through a retrospective study of ALS
SOD1 
natural history, my research 
showed that the most common mutation causing ALS
SOD1 
in North America, Alanine>Valine 
(A4V), is rapidly progressing, while different mutations show a wide range of variability in 
clinical outcomes. I then describe initial characterization of SOD1 protein half-life in the 
cerebrospinal fluid (CSF) of ALS
SOD1
 patients. Similar to healthy control subjects, I found SOD1 
xv 
 
is a long-lived protein in ALS patient CSF, with a half-life on the order of weeks. Moreover, 
A4V SOD1 mutant protein showed differential behavior compared to wild type SOD1 in CSF in 
one ALS participant, preliminarily suggesting that CSF SOD1 measures may implicate the 
pathogenic state of SOD1 protein. Finally, I show that measures of CSF SOD1 protein 
production serve as a pharmacodynamics biomarker for Antisense Oligonucleotides (ASOs) 
treatment targeting SOD1 mRNA transcripts in the central nervous system (CNS). Lowering of 
new SOD1 protein production after ASO treatment preceded lowering of total SOD1 protein 
concentration, suggesting measures of new protein production are more sensitive for mRNA-
targeting therapies and are translatable to human trials to assay drug target engagement. Taken 
together, these data provide insights that contribute to a further understanding of ALS biology, in 




















Chapter 1: Towards a New Treatment for ALS  
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The average life expectancy in the United States has increased from 68 years in 1950 to 
79 years in 2013, and one in four people in the United States are projected to be 65 years or older 
by 2060 (Mather et al 2015). These trends present new challenges to human healthcare, including 
a higher number of people afflicted with diseases associated with aging. Chief among these are 
progressive neurodegenerative diseases, a family of disorders characterized by the loss of 
structure and function of neurons in the brain and spinal cord. Neurodegenerative diseases 
include Alzheimer’s Disease (AD) and other forms of dementia (Alzheimer 1906), Huntington’s 
Disease (HD) (Huntington 1872), Parkinson’s Disease (PD) (Parkinson 1969), and Amyotrophic 
Lateral Sclerosis (ALS) (Charcot 1874). Despite the original descriptions of these diseases over 
two centuries ago, no current cures exist. If the present therapeutic landscape remains 
unchanged, projected costs of neurodegenerative disease patient care will reach over $1 trillion 
by 2050 (WHO 2012). Therefore, a dire societal need exists to develop novel therapies to treat 
these debilitating diseases.   
 Many neurodegenerative diseases converge on a similar pathology in the central nervous 
system (CNS): the accumulation of insoluble protein aggregates within neuronal populations that 
degenerate throughout disease time course. Research into the genetics and pathology that 
underlie these diseases revealed multiple proteins that are prone to misfold and aggregate within 
neurons (Forman et al 2004). These observations have led to a generally accepted hypothesis that 
misfolded proteins impart toxic effects on specific neuronal populations, resulting in cell death. 
Therefore, an attractive therapeutic strategy to treat neurodegenerative diseases is to prevent the 
accumulation of misfolded proteins within the nervous system to maintain neuronal viability 
throughout aging.  
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Despite decades of research that identified potential compounds which ameliorate protein 
aggregation pathologies in disease models, clinical trials for neurodegenerative disorders show a 
failure rate of over 95% (Mitsumoto et al 2014; Petrov et al 2017), and as high as 99% in 
Alzheimer’s Disease (Banik et al 2015; Soejitno et al 2015). Multiple causes may contribute to 
these alarming failure rates, including: a lack of understanding of the mechanisms that govern 
neurodegeneration, the absence of effective tools to measure biological effects of treatments in 
humans, and effective clinical trial design. Moving forward, it is imperative for translational 
researchers to consider all facets of preclinical and clinical research in progressive 
neurodegenerative diseases to bring more effective or curative therapies to patients. Furthermore, 
because neurodegenerative diseases share similar misfolded protein pathologies that converge on 
common mechanisms of neuronal death, the development of an effective treatment in one disease 
condition may provide valuable insight into the development of therapeutic strategies for 
multiple disorders. 
Thus, in an effort to better define the biological and clinical manifestations of 
neurodegenerative disease, the focus of this dissertation will be ALS, colloquially known as Lou 
Gehrig’s Disease, caused by mutations in Superoxide Dismutase 1 (SOD1) (Kiernan et al 2011). 
This dissertation will begin with an introduction to the genetics and clinical characteristics of 
ALS, the role of mutant SOD1 misfolding in ALS pathobiology and clinical phenotypes, the 
development of therapeutic strategies that target SOD1, and previous challenges in translating 
scientific discoveries to effective treatments for ALS caused by SOD1 mutations (ALS
SOD1
). It 
will then discuss the novel research I performed in this dissertation, including a retrospective 
cohort study on the most recent understanding of ALS natural history caused by SOD1 mutations 
in North America, efforts to understand SOD1 involvement in human ALS through analyzing 
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SOD1 protein turnover within the cerebrospinal fluid (CSF) of ALS patients, and the 
development of a new pharmacodynamics biomarker for SOD1-targeting therapies. The 
dissertation will conclude with a discussion of the implications of these studies in translating 
biomedical research into effective therapies for ALS, as well as future research directions for 
both clinical trial design and understanding of human ALS pathobiology.    
Amyotrophic Lateral Sclerosis: A relentless degenerative disorder  
 In 1874, Jean-Marie Charcot first described ALS as a disease of upper and lower motor 
neuron degeneration within the brainstem and spinal cord (Charcot 1874). ALS affects ~3 
individuals per 100,000 in Europe (Worms 2001) and ~5 individuals per 100,0000 in the United 
States (Mehta et al 2016).  ALS is the third most common neurodegenerative disorder in the 
United States, trailing only Parkinson’s Disease and Alzheimer’s Disease (Kiernan et al 2011). 
ALS onset typically begins within the limbs (limb-onset) or facial region (bulbar-onset). 
Symptoms will therefore manifest depending on onset location - with brisk reflexes and local 
muscle wasting in limb-onset ALS or trouble with speech and swallowing in bulbar-onset 
disease (Rowland 2001). Symptoms quickly spread to other regions as additional motor units are 
lost, resulting in spasticity, deep tendon reflexes, fasciculation, wasting, and eventual paralysis 
(Kiernan et al 2011). ALS is rapidly progressive, where 50% of patients with the disease die 
within 30 months from presentation of symptoms and 20% survive between 5 and 10 years after 
symptom onset (Talbot 2009). Currently, ALS is diagnosed by an exclusionary process of 
eliminating all other possible causes of patient symptoms. The lack of an established biomarker 
to accurately diagnose ALS may contribute to poor patient outcomes, as symptoms manifest after 
irreversible degeneration of motor neurons has already occurred in the CNS. Upon diagnosis, 
only two FDA-approved therapies are available for treatment of ALS: Riluzole (Bensimon et al 
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1994; Lacomblez et al 1996; Miller et al 2012), an inhibitor of glutamate release, and Edaravone 
(Abe et al 2017; Kalin et al 2017; Yoshino & Kimura 2006), a free-radical scavenger. These 
treatments are not effective for long-term survival of ALS patients, where the median disease 
progression in randomized control trials slowed by only ~6 months, and controversy remains 
over the reproducibility of results and cost effectiveness of these treatments (Fang et al 2018; 
Messori et al 1999). Therefore, a clear need exists to better understand ALS disease pathogenesis 
for developing treatments that effectively manage or cure this devastating disease.  
Recent advances in genetics have helped to identify potential mechanisms that underlie 
disease pathogenesis in familial forms of ALS, which account for ~10% of total cases 
(Robberecht & Philips 2013). The first gene implicated in ALS, SOD1 (Rosen et al 1993), was 
identified in 1993. For almost 20 years, mutations in SOD1 were the only known cause of 
familial ALS. In the last ten years, researchers have seen an explosion in the discovery of new 
ALS genes that describe ~60% of familial ALS and 11% of sporadic ALS cases (Renton et al 
2014). Of the newly identified genetic causes, the most prevalent are hexanucleotide repeat 
expansions found in the first intron of the C9ORF72 gene, accounting for ~40% of familial ALS 
in the United States and Europe (Majounie et al 2012; Renton et al 2011), and mutations in 
TARDBP and FUS, each accounting for ~5% of familial ALS (Sreedharan et al 2008; Vance et al 
2009). These newly discovered genes  exhibit a variety of proposed functions, including protein 
clearance (UBQLN2 (Deng et al 2011), SQSTM1 (Rubino et al 2012), VCP (Johnson et al 2010), 
TBK1 (Cirulli et al 2015)), vesicle trafficking and cytoskeleton dynamics (PFN1 (Wu et al 2012), 
OPTN (Maruyama et al 2010), TUBA4A (Smith et al 2014), C9ORF72 (Shi et al 2018), 
KIF5A(Nicolas et al 2018)), RNA processing (TDP43 (Ou et al 1995), FUS (Yang et al 1995), 
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MATR3 (Johnson et al 2014), TIA1 (Mackenzie et al 2017)) and reactive oxygen species 
metabolism (SOD1 (McCord & Fridovich 1969b)).  
  ALS is classically described as a motor disorder, but reports suggest that up to 48% of 
ALS patients exhibit cognitive abnormalities associated with frontotemporal lobar degeneration, 
a progressive dementing condition characterized by neuronal loss in the frontal and anterior 
temporal lobes of the brain (Lomen-Hoerth et al 2002; Portet et al 2001). These observations 
suggest that ALS and frontotemporal dementia (FTD) fall on a “spectrum” of neurodegenerative 
disease states. This claim is supported by genetic evidence, where mutations in multiple genes 
cause familial cases of ALS, FTD, and ALS-FTD (Robberecht & Philips 2013). Moreover, the 
majority of sporadic and familial ALS and FTD cases share similar pathological features, such as 
the presence of protein inclusions containing ubiquitin and p62 in neuronal populations affected 
by disease (Neumann et al 2006; Steinacker et al 2008). Although the ALS-FTD spectrum adds 
additional complexity to understanding the individual diseases, the similarity of familial genetics 
and pathologies suggest a potential unifying mechanism of degeneration underlying these 
conditions. 
Although ~80% of ALS cases are sporadic with no known genetic cause, 98% of all ALS 
cases converge on a shared pathology: cytoplasmic protein inclusions containing TDP-43 in 
neurons and glia in the brain and spinal cord (Lomen-Hoerth et al 2002). These observations led 
researchers to hypothesize that modeling familial forms of ALS may reveal common 
mechanisms that mediate ALS pathogenesis to target for therapeutic intervention. Conversely, 
the genetic heterogeneity of ALS may suggest that different ALS subtypes demand unique 
treatment strategies. For example, mutations in SOD1 account for ~2% of all ALS cases and, 
with the exception of one reported patient (Nakamura et al 2015), present without cognitive 
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deficits or TDP-43-related pathology. Instead, the primary protein pathology observed in motor 
neurons is the accumulation of insoluble, ubiquitin-positive aggregates containing mutant SOD1 
protein. Despite these discrepancies in pathology between ALS
SOD1
 and the majority of the ALS 
population, almost 25 years of research in understanding the role of SOD1 in ALS has garnered 
important insights into mechanisms that govern neurotoxicity associated with protein misfolding, 
concurrently leading to the development of novel therapeutic strategies for the treatment of ALS 
and other progressive neurodegenerative diseases.   
The Role of SOD1 in Amyotrophic Lateral Sclerosis  
The SOD1 gene encodes for SOD1, a 153 amino acid, homodimeric, Copper-Zinc 
metalloenzyme that catalyzes the conversion of superoxide anion (O2
-
) into hydrogen peroxide to 
regulate the concentration of reactive oxygen species within cells (McCord & Fridovich 1969a). 
The SOD1 protein contains eight beta-barrel sheets, connecting loops, two intrachain disulfide 
bonds, and two metal-binding domains, with the enzymatic activity of the protein dependent 
upon homodimerization (Parge et al 1992). Rosen and colleagues first identified 11 single 
amino-acid changes in SOD1 on the basis of genomic DNA sequences in members of 13 
different familial ALS families in the United States (Rosen et al 1993). Concurrently, a research 
team in Japan identified a Histidine>Arginine amino acid change at residue 46 (H46R) in two 
familial ALS families in Japan (Aoki et al 1993). Since these initial discoveries, investigators 
have identified over 180 mutations in SOD1 implicated in familial forms of ALS with varying 
degrees of penetrance. These mutations are predominantly missense, but also include nonsense 
and truncation mutations (for an updated list of all SOD1 mutations, visit the ALS Online 
Database). The majority of SOD1 mutations are found in familial ALS, but SOD1 mutations 
have also been reported in sporadic ALS (Chio et al 2009b; Chiò et al 2008).  
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Different SOD1 mutations display a broad spectrum of clinical phenotypes that influence 
disease onset and disease progression after symptom presentation. Interestingly, in contrast to 
other neurodegenerative diseases such as Alzheimer’s Disease where earlier disease onset is 
characterized by more aggressive neurodegeneration and rapid disease progression (Lanoiselee et 
al 2017), early disease onset in ALS
SOD1 
is associated with slower disease progression 
(Cudkowicz et al 1997; Juneja et al 1997; Rosen et al 1994). However, the relationship between 
SOD1 mutation and the heterogeneity of clinical disease characteristics remains poorly 
understood. This complexity is seen in family pedigree analyses, where different SOD1 
mutations display varying degrees of disease  penetrance (Felbecker et al 2010).  For example, 
description of a large family with ALS
SOD1
 caused by an I113T mutation shows 50% penetrance 
at 60 years, with age of onset ranging from 39 – 67 years (Lopate et al 2010).  Given the 
heterogeneity in disease penetrance between mutants, one may hypothesize that mutations which 
cause fast-progressing forms of disease may exhibit higher penetrance. However, an aggressive 
form of ALS
SOD1
 caused by an I112M mutation in four Mediterranean families had several 
obligate carriers in the family pedigree despite an aggressive disease duration of less than 2 years 
(Gamez et al 2011).  The high variability observed between different mutations and within 
families carrying the same SOD1 mutation raises concerns over the validity of these variants as 
disease-causing, making the prognosis of ALS
SOD1
 challenging within the clinic. Therefore, a 
better understanding of mutant SOD1 protein behavior in living patients may provide valuable 
insight into the prognosis of patients carrying these SOD1 variants.   
SOD1 in ALS Pathobiology 
SOD1 mutations that cause ALS are found throughout the entire 153 amino acid protein 
sequence and, with the exception of the D90A mutation in the Scandanavian population 
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(Andersen et al 1997b), display autosomal dominant inheritance. In line with SOD1 genetics, in 
vitro studies have shown that many mutant SOD1 proteins retain enzymatic activity and the 
ability to dimerize with both mutant and WT SOD1 (Borchelt et al 1994; Wiedau-Pazos et al 
1996). Further, knockout of SOD1 in transgenic mice does not result in global motor neuron 
degeneration (Reaume et al 1996; Shefner et al 1999). These data ultimately suggest that SOD1 
loss-of-function is not the primary driver of ALS
SOD1
.  
The common pathology observed in all ALS
SOD1 
patients is the presence of misfolded 
SOD1 protein in ubiquitin-positive, insoluble aggregates within motor neurons (Shibata et al 
1996). Accumulating evidence suggests that mutant, misfolded SOD1 acquires a toxic gain-of-
function which leads to motor neuron degeneration. Indeed, the overexpression of a transgene 
containing the human SOD1 gene with an ALS-causing G93A point mutation in mice was the 
first in vivo model of ALS to show a disease phenotype (Gurney et al 1994). In these transgenic 
mice, mutant SOD1 overexpression causes a rapidly progressing degeneration of motor neurons 
in the brain and spinal cord, muscle atrophy, and hind-limb paralysis by ~6 months of age. These 
animals show the same mutant SOD1 pathology in the brain and spinal cord as human ALS, 
where insoluble protein aggregates are observed in the cell body and processes of motor neurons 
and glial cell types (Johnston 2000; Shibata et al 1998).  These events in transgenic animal 
models appear specific to misfolded, mutant SOD1, as over-expression of WT SOD1 protein 
does not result in an ALS-like phenotype of motor neuron degeneration (Avraham et al 1988; 
Chan et al 1998). Additionally, WT SOD1 overexpression in the presence of mutant SOD1 does 
not accelerate the rate of disease in vivo (Bruijn 1998).  
Many mechanisms by which misfolded SOD1 causes motor neuron toxicity have been 
suggested including impaired protein clearance due to proteasome (Cheroni et al 2009; 
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Matsumoto et al 2005; Urushitani et al 2002) and autophagy (Bandyopadhyay et al 2014; 
Rudnick et al 2017; Xie et al 2015) inhibition, mitochondrial dysfunction (Ferri et al 2006; 
Israelson et al 2010; Jaarsma et al 2001; Li et al 2010; Liu et al 2004; Pasinelli et al 2004; Vande 
Velde et al 2008), endoplasmic reticulum stress (Filezac de L'Etang et al 2015; Lee et al 2016b; 
Nagano et al 2015; Saxena et al 2009), and impaired axonal transport (Williamson & Cleveland 
1999). Because motor neurons are selectively vulnerable to degeneration in ALS, early efforts 
focused on understanding motor neuron-specific cellular mechanisms that contribute to disease. 
However, conditional overexpression of mutant SOD1 in neurons yielded conflicting results. 
Driving expression of mutant SOD1 with a neuron-specific promoter was not sufficient to 
recapitulate the motor neuron degeneration observed with ubiquitous expression of mutant SOD1 
in vivo (Pramatarova et al 2001).  Other reports showed a mild motor neuron degeneration 
phenotype in mice conditionally overexpressing mutant SOD1 in neurons using the Thy1 
promoter (Jaarsma et al 2008). However, the Thy1 promoter is also expressed in glial cells, 
which confounds the interpretation of degeneration driven by neuron-specific expression of 
SOD1 (Kemshead et al 1982). Also, SOD1 pathology is not restricted to motor neurons, as early 
characterization of transgenic G85R SOD1 mouse models and human autopsies reported 
inclusions of misfolded SOD1 and downregulation of glial glutamate transporters in astrocytes 
(Bruijn et al 1997; Kato et al 2000; Lin et al 1998). These observations suggest that cell-
autonomous effects of mutant SOD1 in motor neurons are not solely responsible for ALS 
pathology.  
Seminal experiments in vivo and in cell culture further revealed the importance of non-
neuronal cell types as contributors to neurotoxicity caused by expression of mutant SOD1. 
Chimeric mice expressing WT human SOD1 in glial cells and mutant G37R SOD1 in motor 
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neurons exhibited extended survival compared to mice that ubiquitously express mutant SOD1 
(Clement et al 2003). These results were corroborated by genetic experiments where conditional 
knockout of mutant SOD1 was performed using a Cre-Lox recombinase system. In this 
paradigm, removal of G37R SOD1 in motor neurons resulted in delayed onset of disease without 
altering disease progression. However, conditional knockout of G37R SOD1 in either astrocytes 
or microglia drastically delayed disease progression (Boillee 2006). Similar removal of mutant 
SOD1 from oligodendrocyte progenitors delayed disease onset and progression in transgenic 
animal models (Kang et al 2013). Glial cells may also directly contribute to motor neuron 
toxicity. Co-culture of astrocytes and oligodendrocytes expressing mutant SOD1 is sufficient to 
induce motor neuron cell death. This toxicity is independent on cellular contact, as conditioned 
media from glial cell cultures is also sufficient to induce motor neuron toxicity in vitro (Di 
Giorgio et al 2008; Di Giorgio et al 2007; Ferraiuolo et al 2016). It is unknown if this toxicity 
caused by glia is due to the release of a secreted neurotoxic factor or the result of critical nutrient 
depletion for motor neurons by mutant-expressing glial cells. In sum, these data highlight the 
critical role of mutant SOD1 expression in glia in mediating motor neuron degeneration in ALS 
by non-cell autonomous mechanisms independent of motor neuron function.  
One of the proposed mechanisms that drive mechanisms of toxicity in ALS is 
inflammation, which involves multiple cell types in both the CNS and periphery.  Compromised 
blood brain barrier and pericyte dysfunction are early pathological hallmarks of mutant SOD1 
transgenic animal models (Zhong et al 2008), indicative of inflammation within the brain and 
spinal cord. Outside of the CNS, ALS
SOD1
 patients present with compromised T-cell function, 
resulting in a pro-inflammatory profile that correlates with disease severity and progression 
(Beers et al 2017). Within the CNS, mutant SOD1 secreted from neurons can be phagocytosed 
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by surrounding microglia, causing a pro-inflammatory activation of microglia that is ultimately 
neurotoxic (Meissner et al 2010; Urushitani et al 2002; Zhao et al 2010).  This role of 
inflammation in ALS disease progression further demonstrates that non-cell autonomous 
mechanisms are not restricted to intracellular activity of mutant SOD1.  
The discovery of many non-cell autonomous mechanisms of mutant SOD1 toxicity in 
neurons, glia, and peripheral immune cells adds to the complexity of ALS disease pathogenesis 
and helps explain the challenges in developing current treatments for patients. However, the 
diversity of pathways also provides an opportunity for the development of different therapeutic 
strategies to effectively target and ameliorate SOD1-mediated pathology. Furthermore, the wide 
array of pathways implicated in ALS also suggest that targeting of SOD1 in all cell types 
throughout the entire CNS is important for developing an effective treatment strategy.  
An attractive hypothesis relating SOD1 behavior to these toxic pathways, and ultimately 
to clinical outcomes, is that SOD1 mutations which cause greater protein destabilization result in 
more rapidly progressing forms of disease by catalyzing the conversion of mutant SOD1 into 
toxic, misfolded protein species. This hypothesis is supported by experiments using recombinant 
SOD1 protein in vitro. Shi and colleagues demonstrated that the failure of dimerization between 
mutant and wild type SOD1 protein correlates with a more rapid disease progression (Shi et al 
2016). Additional analyses of point mutations at the G93 residue in recombinant SOD1 protein 
showed a positive correlation between the propensity for protein aggregation and disease 
progression (Pratt et al 2014). In patients, Sato and colleagues tested the hypothesis that unstable 
SOD1 mutant protein species would be rapidly turned over and undetectable in anuclear red 
blood cells. Indeed, they reported that patients who carried SOD1 mutant protein that was not 
detectable in red blood cells exhibited a more rapid disease progression compared to detectable 
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mutant SOD1 protein carriers (Sato et al 2005). Despite the promise of these suggestive 
correlations, no current data characterizes the biochemical behavior of mutant and wild type 
SOD1 in the CNS of ALS patients, limiting understanding of the biological relevance of these 
findings to disease.   
Despite extensive descriptions of SOD1 misfolding and aggregation in post mortem brain 
and spinal cord tissues of ALS patients, the ability to effectively analyze pathological SOD1 
behavior in the CNS of living ALS patients remains elusive. For other neurodegenerative 
diseases, researchers developed imaging agents that bind to protein aggregates such as amyloid-β 
and microtubule associated protein tau in Alzheimer’s disease to visualize protein misfolding by 
positron emission tomography (Klunk et al 2004; Villemagne et al 2018). These imaging agents 
are able to bind to β–sheet rich, amyloid aggregate structures and have been instrumental in 
characterizing the pathological events that underlie neurodegeneration in AD. By contrast, 
misfolded SOD1 forms an amorphous, non-amyloid aggregate, thereby limiting the development 
of such agents to identify SOD1 misfolding in ALS (Kerman et al 2010; Mulligan et al 2012).   
The primary methods used to tackle this unmet need in ALS are assays that measure 
SOD1 protein levels in CSF of patients via enzyme-linked immunosorbent assay (ELISA) or 
SOD1 activity assays. However, all studies fail to measure significant differences in CSF SOD1 
between ALS
SOD1
 from controls. Jacobsson and colleagues showed no difference in CSF SOD1 
protein activity between ALS
SOD1
, sporadic ALS, and control patients (Jacobsson et al 2001). 
Further, Zetterstrom and colleagues developed a misfolded SOD1-specific ELISA and tested for 
differences in levels of misfolded SOD1 in CSF of 38 neurological controls and 96 ALS patients. 
Misfolded SOD1 was present in all samples, but further analysis could not distinguish between 
ALS and controls, or ALS
SOD1
 and sporadic ALS (Zetterstrom et al 2011). In a separate cohort, 
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Winer and colleagues reported in an increase in CSF SOD1 levels in ALS
SOD1
 compared to 
healthy controls. However, CSF SOD1 was also elevated in neurological disease controls, 
questioning the specificity of this result to ALS (Winer et al 2013). A key limitation in the 
development of SOD1 assays is the challenge of discriminating mutant and WT SOD1 in any 
measure. Most single amino acid changes caused by mutations do not drastically change any 
bulk biochemical properties of the SOD1 protein such as molecular weight that can be resolved 
by methods such as gel electrophoresis. Moreover, single amino acid changes make the 
development of novel antibodies that specifically recognize mutant SOD1 protein challenging. 
Given these conflicting data, a clear need exists to further investigate SOD1 in human ALS to 
better understand its role in both familial and sporadic forms of the disease. 
Controversial Role of SOD1 in Sporadic ALS  
Because protein misfolding is a hallmark of ALS, and mutant SOD1 protein is prone to 
misfolding and aggregation, researchers have investigated the potential for wild-type SOD1 
protein to misfold and aggregate. Such data may implicate misfolded SOD1 as a common 
disease mechanism in both familial and sporadic forms of ALS in which SOD1 is not mutated. In 
vitro perturbations to WT SOD1 such as demetallation and oxidation cause protein misfolding 
and denaturation (Rakhit et al 2002; Rodriguez 2002), and these misfolded WT SOD1 species 
share similar conformations with mutant SOD1 variants (Durazo et al 2009). Further, co-
expression of mutant SOD1 protein with WT SOD1 protein in cell culture induces WT SOD1 
misfolding using a disease-specific epitope antibody (Grad et al 2011).  In vivo, crossing mutant 
SOD1 transgenic mice with WT SOD1 transgenic mice results in the identification of WT SOD1 
in detergent-insoluble spinal cord fractions (Prudencio et al 2010). Additionally, overexpression 
of A4V SOD1 in transgenic mice does not show an ALS phenotype unless crossed with human 
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WT SOD1-expressing transgenic mice to co-express both mutant and WT SOD1 protein (Deng 
et al 2006). A key limitation of these studies is the use of overexpression paradigms and high 
concentrations in vitro, which calls into question the validity of WT SOD1 misfolding in human 
ALS pathophysiology.  
Despite these observations from mouse models, evidence for misfolded WT SOD1 in 
either human ALS
SOD1
 or sporadic ALS without SOD1 mutations is conflicting. In post-mortem 
studies, multiple groups have reported misfolded SOD1 in sporadic ALS spinal cord autopsies 
(Bosco et al 2010; Forsberg et al 2010). However, these findings appear to be antibody-specific, 
as results could not be recapitulated using different antibodies that recognize misfolded SOD1 
protein with overlapping epitopes (Da Cruz et al 2017). Moreover, each of these post-mortem 
studies have a relatively small sample sizes to test for misfolded SOD1 positivity in sporadic 
ALS samples, limiting the generalizability and interpretation of results.  
The limited number of assays that exist to determine the state of misfolded SOD1 protein 
in living patients also presents challenges in implicating misfolded SOD1 in sporadic ALS. The 
identification of misfolding of wild type SOD1 in sporadic ALS is a key outstanding question for 
identifying the relevance of SOD1-targeting therapeutics for ALS outside SOD1 mutant carriers. 
Interestingly, lowering of SOD1 in sporadic ALS astrocytes reduces motor neuron toxicity in cell 
culture (Haidet-Phillips et al 2011), suggesting that therapeutic targeting of SOD1 may be 
beneficial in sporadic ALS. Further data clarifying the role of SOD1 in sporadic ALS may 
broaden the utility of SOD1-targeting therapies beyond the ~2% of ALS patients that have 
disease caused by SOD1 mutations.    
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Toxicity by Misfolded SOD1: Similarity to other ALS subtypes 
Although the presence of misfolded SOD1 pathology outside of ALS
SOD1 
remains 
controversial, the gain-of-toxicity function associated with misfolded proteins may be a common 
mechanism that unites many disease subtypes, as other proteins implicated in ALS pathobiology 
are prone to misfolding and aggregation. In patients who harbor expansions in the first intron of 
C9ORF72 gene, the GGGGCC expansion is unconventionally translated by a non-ATG-related 
mechanism to produce dipeptide-repeat proteins that are prone to misfolding and form insoluble 
protein aggregates within cells (Ash et al 2013; Mori et al 2013a; Mori et al 2013b; Zu et al 
2013). Similar to misfolded SOD1, these dipeptide-repeat proteins are toxic to neurons in vitro 
(Donnelly et al 2013; Kwon et al 2014; Mizielinska et al 2014) and in vivo (Chew et al 2015; Liu 
et al 2016). Additionally, full-length and C-terminal fragments of TDP-43 found in familial and 
sporadic ALS have the ability to induce TDP-43 misfolding and aggregation that is toxic to 
neurons (Fang et al 2014; Nonaka et al 2013). Mechanisms of toxicity that have been proposed 
for these misfolded protein species are similar to misfolded SOD1(Sareen et al 2013). Therefore, 
an understanding of toxicity caused by misfolded SOD1 protein may provide the foundations to 
develop therapeutic strategies in other forms of ALS that target different pathological proteins to 
test in randomized control clinical trials.  
Learning from Past Failures for ALS
SOD1
 Clinical Trial Design  
 The average success rate of drug development programs reaching market approval for use 
in patients is ~14% (Wong et al 2018). This low probability of success highlights the difficulties 
in developing novel therapies for any disease indication. The situation is even more dire in ALS, 
where over 50+ randomized control trials have led to two, marginally effective FDA-approved 
treatments (Mitsumoto et al 2014). Despite failure rates of over 95% for ALS randomized 
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control trials, previous efforts gleaned valuable lessons to identify key factors that influence 
successful clinical trial design. Among these factors include a growing appreciation for the 
heterogeneity of clinical disease characteristics in ALS and the need for adequate tools inform on 
the biological efficacy of a drug.  
 Developments in DNA sequencing techniques have provided tremendous insight into the 
genetic complexity of disease where, in cases like cancer tumors, subpopulations of cells may 
exhibit unique genomic alterations (Fisher et al 2013). Indeed, the growing number of mutations 
implicated in ALS
 
suggests that different subtypes of ALS may exist which still result in the 
same motor neuron degeneration phenotype. Further, natural history data from all ALS patients 
shows median survival time from onset to death ranges from 20 to 48 months, but 10-20% of 
ALS patients have survival longer than 12 years (Chio et al 2009a). If we accept the hypothesis 
that different rates of disease progression are the result of multiple ALS phenotypes, therapeutic 
efficacy of a new treatment may vary between different ALS populations. With the absence of 
established prognostic biomarkers for ALS in neurology clinics, the most valuable data available 
to help understand clinical outcomes are previous epidemiology studies of natural history in the 
ALS population. Therefore, a key component for future trial design is to understand the natural 
history of the disease in different genetic, geographic, and topographic variables in ALS 
populations.  
One proposed solution to account for these differing clinical phenotypes in randomized 
control trial design is to stratify participants into fast- and slow-progressing ALS subgroups for 
analysis. Indeed, most researchers design ALS randomized control trials to monitor clinical 
outcomes after a 12-18 month period. This relatively short time frame demands recruitment of 
patients with fast progressing phenotypes to accurately capture changes in survival during the 
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course of a trial. This challenge of trial design is further magnified by the rarity of ALS (~30,000 
patients in the United States) (Kiernan et al 2011), limiting the number of patients available for 
recruitment into a randomized control trial.  
Another proposed solution to address the challenges of disease heterogeneity is the use of 
historical controls as an alternative to randomized, placebo-treated participants. For example, a 
multicenter, randomized control trial testing the efficacy of lithium carbonate in improving 
survival enrolled 107 unique ALS patients and matched these participants with 249 historical 
controls pooled from previous trials (Miller et al 2011). For subpopulation stratification or the 
use of historical controls to be effective in a prospective trial design, it is imperative to 
understand if clinical disease characteristics change over time, as improvements in standard of 
care may confound the ability to accurately match or stratify ALS subpopulations for effective 
interpretation of treatment efficacy. 
An additional glaring failure of previous ALS clinical trials is the lack of tools to 
properly determine drug target engagement, ie.) pharmacodynamics biomarkers, in the CNS. 
From 2004 – 2014, researchers performed 23 large, multicenter, randomized clinical trials for 
disease-modifying ALS drugs with multiple therapeutic targets (Aggarwal et al 2010; Beghi et al 
2013; Berry et al 2013; Chiò et al 2010; Cudkowicz et al 2013; Cudkowicz Merit et al 2006; 
Dupuis et al 2012; Gordon et al 2007; Graf et al 2005; Kaufmann et al 2009; Lauria et al 2009; 
Meininger et al 2006; Meininger et al 2004; Meininger et al 2009; Milane et al 2009; Miller et al 
2007; Mosley et al 2007; Pascuzzi et al 2010; Rosenfeld et al 2008; Shefner et al 2004; Sorenson 
et al 2008; Verstraete et al 2012). All trials failed to show a difference in the primary clinical 
outcomes of survival or change in the ALS Functional Rating Scale (ALSFRS) compared to 
placebo. Further, 22 of the 23 trials lacked a pharmacodynamics biomarker to determine if the 
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experimental drug effectively engaged with its intended pathological target. Equally troubling, 
recent phase III randomized control trials whose data supported the approval of Edaravone failed 
to analyze the drug’s mechanism of action to scavenge free radicals in the CNS (2017; Abe et al 
2017).  Failure to identify drug target engagement limits the interpretation of all results in these 
trials, as investigators confine interpretation of results to assessment of clinical effects. These 
analyses leave an understanding of the underlying human biology with the experimental 
treatment unknown. Especially in a disease such as ALS with unknown pathogenesis, it is 
essential to understand if new treatments have any biological effects on desired targets to modify 
hypotheses in the field and focus new drug development efforts. Despite the progress of 
technologies to assay biofluid-based markers of neurodegeneration such as neurofilament light-
chain in plasma and CSF (Bacioglu et al 2016; Gaiani et al 2017; Lu et al 2015) or extracellular 
domain P75 in urine (Shepheard et al 2017), no methods currently exist to test objective 
biomarkers in ALS patients. Therefore, investigators must strive to include pharmacodynamics 
biomarkers in trial design to provide more insight into the relationship between improved clinical 
outcomes to effective changes in ALS pathobiology.  
Therapeutic Strategies for ALS
SOD1 
Given the accumulating evidence of mutant SOD1 toxicity to motor neurons, an 
attractive therapeutic strategy is to eliminate the presence of misfolded SOD1 protein species 
within the CNS. The predominant strategies under investigation for targeting misfolded SOD1 
protein in neurons include: 1) promoting clearance of misfolded SOD1 protein through the 
ubiquitin-proteasome system and autophagy degradation pathways, 2) enhancing the activity of 
SOD1 molecular chaperones to prevent protein misfolding, and 3) lowering protein synthesis of 
SOD1 within cells. Despite studies demonstrating improved survival in preclinical disease 
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models using these therapeutic strategies, key limitations inhibited translation of these 
approaches to successful clinical trials in human ALS patients.  
Cells clear mutant SOD1 through the ubiquitin-proteasome system (UPS) and autophagy 
pathways (Kabuta et al 2006). These pathways provide investigators with multiple targets to test 
the hypothesis that enhanced mutant SOD1 protein clearance will lead to improved disease 
outcomes. Indeed, researchers identified multiple E3 ligases that specifically interact with mutant 
SOD1 to promote protein clearance within motor neurons. Overexpression of the E3 ligases 
Dorfin and NEDL1 led to reduced motor neuron toxicity by mutant SOD1 in vitro and increased 
overall survival in transgenic animal models (Miyazaki et al 2004; Niwa et al 2002; Sone et al 
2010). Additionally, treatment with small molecules that increase proteasome activity (Lee et al 
2010) and mTOR-dependent autophagy (Castillo et al 2013; Gomes et al 2010) enhance the 
clearance of misfolded proteins and reduce neuronal toxicity in cell culture.  
However, conflicting studies cast doubt on the feasibility of targeting the UPS and 
autophagy pathways in vivo. In the case of autophagy, treatment with rapamycin led to an 
exacerbation of motor neuron degeneration in SOD1
G93A
 transgenic mice (Zhang et al 2011). 
Similarly, treatment with another small molecule, trehalose, to enhance autophagy in SOD1
G85R
 
transgenic mice saw improvements in overall survival but did not alter disease onset. These 
results suggest authophagy enhancement is not sufficient to ameliorate all motor neuron toxicity 
caused by mutant SOD1. Moreover, the importance of ubiquitin in synaptic maintenance (Wilson 
et al 2002) suggests that enhancing proteasome activity may result in detrimental effects to 
neurons. Therefore, despite an understanding of the role that these pathways play in the clearance 
of mutant protein from cells, the complexities of these molecular pathways in vivo have hindered 
the development of an effective therapeutic strategy targeting protein clearance mechanisms.  
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Similar challenges are seen in the development of strategies to prevent protein misfolding 
by enhancing the unfolded protein response (UPR) and molecular chaperones associated with the 
heat shock proteins (Lindquist 1986). Researchers hypothesized that these target pathways would 
enhance the stability of mutant SOD1 and prevent toxic protein misfolding and aggregation for 
efficient protein clearance. Researchers observed initial promise when SOD1
G93A
 transgenic 
mice treated with arimoclomol, a co-inducer of heat shock protein expression through the 
activation of heat shock factor-1, resulted in increased survival (Kieran et al 2004), leading to a 
randomized control trial to test arimoclomol in ALS patients (Benatar et al 2018). Also, Nagy 
and colleagues demonstrated that transgenic overexpression of the chaperone HSP110 improves 
survival in SOD1
G85R
 transgenic mice without altering SOD1 mRNA or protein levels (Nagy et 
al 2016). However, activation of other heat shock proteins do not exhibit a similar response, as 
overexpression of HSP70 in SOD1
G93A
 transgenic mice is not sufficient to reduce mutant SOD1 
protein toxicity (Liu et al 2005). Moreover, inhibition of HSP90 by a small molecule showed 
opposite effects in lowering misfolded protein toxicity in vitro and in vivo (Cha et al 2014), 
providing insight into the tight regulation of the HSP protein family in vivo. Therefore, these 
conflicting data highlight that although HSP chaperones and regulators of cellular stress response 
pathways are an attractive target for therapeutic intervention, complications of specificity, 
sustained activation, and compensatory mechanisms of different chaperones result in the absence 
of effective drug candidates for treatment of ALS.  
The complications associated with targeting the maintenance of SOD1 led researchers to 
test a therapeutic intervention further upstream of proteostasis: the production of new SOD1 
protein. Because most SOD1 mutations are caused by a single missense mutation, current 
technologies are limited in their ability to specifically target the mutant allele. However, the 
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observation that genetic deletion of the SOD1 gene is generally well-tolerated in vivo (Reaume et 
al 1996; Shefner et al 1999) suggests that therapeutics lowering global SOD1 synthesis is 
feasible. However, identification of small molecule therapeutics that lower SOD1 transcription 
remains elusive, as Wright and colleagues failed to identify any small molecules that alter SOD1 
promoter activity from a screen of 1,040 FDA-approved compounds (Wright et al 2010).  
Further downstream from transcriptional control, another attractive strategy includes 
RNAi-based SOD1 gene silencing. Two parallel studies initially demonstrated the therapeutic 
efficacy of RNAi-based approaches in vivo by transducing SOD1
G93A
 transgenic mice with 
lentiviral vectors expressing short-hairpin RNA (shRNA) targeting SOD1 mRNA transcripts. 
Ralph and colleagues demonstrated that  intramuscular lentiviral injection of SOD1 shRNA 
delayed disease onset by 100% and increased survival by more than 80% (Ralph et al 2005b). 
Concurrently, Raoul and colleagues showed increases in overall survival of 20%  compared to 
untreated animals after intraspinal lentivirus injection (Raoul et al 2005). In both instances, 
improvements in survival were the result of delaying motor neuron degeneration in the CNS, as 
Miller and colleagues showed that restricted SOD1 mRNA silencing in muscle is not sufficient 
to improve animal survival (Miller et al 2006). Further advancements in the delivery of SOD1 
shRNA by adenoviral vector AAV9 showed improvements in delayed disease onset and overall 
survival through peripheral administration (Foust et al 2008) and injection into the motor cortex 
(Thomsen et al 2014) of SOD1 transgenic models.  
Despite the promise of RNAi-based approaches in preclinical models of ALS
SOD1
, 
significant traction fails to exist for translation to clinical trials. Lack of progress for a DNA-
based therapeutic strategy is primarily driven by continued safety concerns with viral packaging 
in which there is no ability to “turn off” shRNA expression. Additionally, the need for shRNA to 
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be processed by endogenous transcriptional machinery such as Dicer and Argonaute proteins 
presents risks of toxicity through competition with endogenous mRNAs for proper RNA 
homeostasis. Indeed, Grimm and colleagues showed that high levels of shRNA within liver cells 
result in oversaturation of  micro-RNA processing machinery, leading to animal fatality (Grimm 
et al 2006). Due to these concerns, an opportunity exists for an alternative approach that utilizes 
RNAi independent of viral-based approaches that uses alternative cellular machinery. One such 
treatment that has gained significant traction is the use of antisense oligonucleotides.  
Antisense Oligonucleotides for the Treatment of ALS
SOD1
 
Antisense oligonucleotides (ASOs) are short, single-stranded sequences of DNA 
composed of a phosphate backbone and ribose sugar rings (Schoch & Miller 2017). ASOs bind 
by standard Watson-Crick base pairing (Watson & Crick 1953) to specific mRNA in the nucleus 
and cytoplasm of cells to exert gene modulating effects. The sequence design and chemical 
modifications to the phosphate backbone and sugar groups result in multiple potential 
mechanisms of action for ASOs, including mRNA transcript degradation by recruitment of 
RNase enzymes (DeVos & Miller 2013a), splicing modifications (Schoch et al 2016), stalling of 
translation (Bennett & Swayze 2010), or targeting microRNAs (Janssen et al 2013; Koval et al 
2013). ASOs present multiple advantages over shRNA technology for RNAi-based therapies. 
First, ASOs are readily taken up by tissues, most likely through interaction with high- and low-
binding plasma proteins, internalized into lysosomal or endosomal compartments, and trafficked 
within cells (Geary et al 2015). Further, chemical modifications increase resistance of ASOs to 
nuclease degradation and eliminate toll-like receptor responses (Henry et al 2000), resulting in 
superior pharmacokinetic properties of ASOs without the need for viral packaging. Although 
these highly negatively charged DNA-like molecules do not cross the blood brain barrier, 
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empirical data in non-human primates demonstrates that intrathecal delivery of ASOs results in 
broad distribution within the CNS (DeVos et al 2017; Kordasiewicz et al 2012; Smith et al 
2006). Researchers performed the  first clinical trials using ASOs in acute myelogenous 
leukemia (Bayever et al 1993) over 25 years ago, and the first market approval for an antisense 
therapeutic for the treatment of cytomegalovirus retinitis in patients with immunodeficiency 
occurred in 1998 (Marwick). These previous successes highlight the feasibility of using ASOs 
for the treatment of human disease. Indeed, the recent approval of ASO treatments for two 
neuromuscular diseases: Duchenne muscular dystrophy (Mendell et al 2016) and spinal muscular 
atrophy (Finkel et al 2017) further supports the prospects of translating ASO treatments for 
neurodegenerative diseases into medical practice.  
As with previous studies using shRNA, ALS
SOD1
 is an ideal candidate on which to test an 
ASO therapy. Using ASOs that contain a phosphorothioate DNA backbone designed to recruit 
RNase H effectively degrade SOD1 mRNA transcripts (Wu et al 2004). Smith and colleagues 
first demonstrated the broad distribution of these SOD1-lowering ASOs in the CNS after 
infusion into cerebrospinal fluid (CSF) in rats and rhesus monkeys. ASOs targeting human 
SOD1 mRNA resulted in global lowering of SOD1 mRNA in the brain and spinal cord and 
improved survival of SOD1
G93A
 transgenic rats relative to saline-treated animals by ~10% (Smith 
et al 2006). Further optimization of SOD1 ASOs for sequence specificity and tolerability led to 
increases in overall survival of ~40% with a single, intrathecal bolus injection of SOD1 ASO 
compared to artificial CSF-treated animals (McCampbell et al 2018). Excitingly, SOD1 ASOs 
administered via intrathecal injection were shown to be safe in a human Phase I clinical trial 
(Miller et al 2013). This pioneering work in the use of ASOs for ALS
SOD1
 has led to the 
development of ASOs for the treatment of other neurodegenerative diseases such as Alzheimer’s 
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Disease (DeVos et al 2017), Huntington’s Disease (Kordasiewicz et al 2012), and Parkinson’s 
Disease (Zhao et al 2017b) that are being pursued in human randomized control clinical trials. 
Despite these promising data, key challenges in clinical trial execution remain for successful 
translation of SOD1 ASOs as effective therapeutics for SOD1
ALS
. 
Considerations for ASO Clinical Trial Design in ALS
SOD1
  
Because of the unresolved role of SOD1 outside of ALS
SOD1
, current ASO clinical trials 
limit patient population recruitment to those patients with known SOD1 mutations. This 
population only accounts for ~2% of all ALS cases, drastically lowering the number of subjects 
available. As previously discussed, the ALS
SOD1
 population displays heterogeneity in clinical 
phenotypes dependent upon each mutation. The mean disease duration of ALS
SOD1
 is 3.9 ± 5.5 
years (Cudkowicz et al 1997; Juneja et al 1997), ranging from rapidly progressing disease with a 
mean disease duration of ~1 year such as A4V (Rosen et al 1994), to slowly progressing disease 
where patients live 20+ years after diagnosis such as I104F (Abe 1997) and  I151T (Kostrzewa et 
al 1996). A4V is a mutation of particular interest, as it accounts for ~50% of North American 
ALS
SOD1
 with little variability in disease progression (Juneja et al 1997). With a high percentage 
of rapidly progressing patients and a rare disease population, an SOD1 ASO clinical trial may 
benefit from stratification and the use of historical controls. However, multicenter ALS
SOD1 
natural history studies past the year 2000 are largely absent, as most current research focuses on 
characterization of newly identified SOD1 mutations. Thus, recent changes to ALS
SOD1 
prognosis 
are not well understood. It is possible that advancements in ALS standard of care have improved 
ALS
SOD1
 patient outcomes. Supporting this claim, a retrospective analysis of ALS patients cared 
for from 1984 – 1999 and 1999 – 2004 suggests improvement to contemporary patient standard 
of care in the 21
st
 century (Czaplinski et al 2006b).  Therefore, it is important to understand if 
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revised disease management results in changes to ALS
SOD1
 epidemiology since initial 
characterization of SOD1 mutations in the late 1990s for the optimization of current SOD1 ASO 
clinical trial design.  
 In contrast with previous trials, targeting SOD1 by ASO treatment provides an exciting 
opportunity to incorporate pharmacodynamics biomarkers into outcomes measures. Lowering of 
SOD1 mRNA and protein in brain and spinal cord leads to subsequent lowering of CSF SOD1 
protein levels after ASO treatment in ALS rodent and non-human primate models (McCampbell 
et al 2018; Winer et al 2013). As mRNA is difficult to isolate from CSF, it is encouraging to 
demonstrate the feasibility of more easily available, protein-based ASO pharmacodynamics 
biomarkers. Moreover, these data provided the rationale to evaluate the effects of ASO treatment 
on SOD1 protein in CSF as a secondary objective in an ongoing SOD1 ASO Phase I trial 
(NCT02623699). However, in a rapidly progressing disease such as ALS, it is imperative to 
assess treatment efficacy as quickly as possible to maximize patient outcomes. To that end, 
SOD1 protein measurement in CSF may not be the fastest assessment of ASO 
pharmacodynamics. Protein concentration is dependent on both the production of new protein, 
but also on the clearance of existing protein as determined by protein half-life. SOD1 is a long-
lived protein in the human CNS, with a previously calculated half-life of ~25 days in CSF (Crisp 
et al 2015) . Therefore, further potential exists to develop pharmacodynamics biomarkers that 
more directly and quickly reflect the mechanism of ASO action to lower target mRNA levels and 
inhibit the synthesis of new protein.     
Summary of Dissertation  
 The work in subsequent chapters represents new insights into the translation of 
preclinical drug candidates toward new therapies for ALS
SOD1
. Chapter 2 describes the largest 
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effort in the last 20 years to study the natural history of ALS
SOD1
 in North America. In this 
retrospective cohort study analyzing 175 ALS
SOD1
 patients cared for past the year 2000, I found 
that mean age of onset and median survival of ALS caused by SOD1 mutations is consistent 
across previous natural history studies. Additionally, I demonstrated that the A4V point mutation 
remains an aggressive form of disease with a significantly shorter median survival after symptom 
onset with lower variability compared to non-A4V mutation carriers. Given that the A4V 
mutation is the most common variant in North America, my power analysis suggests that the 
design of a randomized control trial with SOD1 A4V carriers to test therapeutic interventions in 
ALS
SOD1
 is possible.  
Chapter 3 describes my efforts to characterize SOD1 protein turnover in the CSF of ALS 
participants using stable isotope labeling kinetics (SILK) analysis (Bateman et al 2006). We 
describe preliminary results to characterize SOD1 protein behavior in the CSF of both ALS
SOD1
 
and sporadic ALS patients. Similar to normal controls, SOD1 is a long-lived protein in the CSF 
of ALS participants, with a protein half-life of ~20-25 days. Excitingly, I also show that mutant 
SOD1 protein exhibits different behavior than WT SOD1 in the CSF of SOD1 mutant carriers, as 
a participant harboring an A4V SOD1 mutation exhibits changes in CSF protein behavior 
between mutant and wild-type protein. Interestingly, two participants with different SOD1 
mutations (E100K, A89V) show similar CSF SOD1 protein behavior compared to WT SOD1. 
These data suggest that, similar to the differences in ALS
SOD1
 clinical phenotypes by mutation, 
different SOD1 mutant proteins may show differential biochemical properties in human CSF.   
Chapter 4 highlights the development of a protein-based pharmacodynamics biomarker 
for ASO treatment in the CNS. Using a stable isotope labeling method to measure incorporation 
of 
13
C6-leucine into newly produced proteins after ASO treatment, I show significant lowering of 
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target protein synthesis in CNS tissues and CSF after ASO treatment in transgenic animal 
models. Excitingly, we observed lowering of target protein synthesis at an earlier time point than 
protein concentration-based measures in tissue and CSF, suggesting that new protein production 
may be a more sensitive pharmacodynamics biomarker than protein concentration in clinical 
trials. The final chapter will then discuss these results and consider future directions for research 











Chapter 2: Defining SOD1 ALS Natural History to Guide 




Understanding the natural history of familial amyotrophic lateral sclerosis (ALS) caused 
by SOD1 mutations (ALS
SOD1
) will provide key information for optimizing clinical trials in this 
patient population. In this study, we sought to establish an updated natural history of ALS
SOD1
 in 
a retrospective cohort study from 15 medical centers in North America. We evaluated records 
from one hundred seventy-five ALS patients with genetically confirmed SOD1 mutations, cared 
for after the year 2000. Age of onset, survival, ALS function rating scale (ALS-FRS) scores, and 
respiratory function were analyzed as primary measures.  Patients with the A4V (Ala-Val) SOD1 
mutation (SOD1
A4V
), the largest mutation population in North America with an aggressive 
disease progression, were distinguished from other SOD1 mutation patients (SOD1
Non-A4V
) for 
analysis. Mean age of disease onset was 49.7 ± 12.3 years (mean ± standard deviation) for all 





Kruskal-Wallis).  Total SOD1 patient median survival was 2.7 years. Mean disease duration for 




 survival probability 
(median survival 1.2 years) was significantly decreased compared to SOD1
Non-A4V
 (median 
survival 6.8 years) (p<0.0001, log-rank). A statistically significant increase in ALS-FRS decline 
in SOD1
A4V
 compared to SOD1
Non-A4V
 subjects (p=0.02) was observed, as well as a statistically 





Similar to previous investigations, SOD1
A4V
 remains an aggressive, but relatively homogeneous 
form of ALS.  These SOD1-specific ALS natural history data will be important for the design 
and implementation of clinical trials in the ALS
SOD1





Amyotrophic lateral sclerosis (ALS) is an adult-onset neurodegenerative disease affecting 
both upper and lower motor neurons, resulting in severe weakness and fatal respiratory failure 
within 2-5 years.  The annual incidence of ALS is 1.7 in 100,000 people (Sorenson et al 2002), 
yet the only FDA-approved treatment, riluzole, has minimal effects on disease course(Miller et al 
2009). 
Inherited or familial ALS (FALS) accounts for roughly 10% of all ALS cases(Byrne et al 
2011).  The second most common cause of FALS is the gene encoding copper zinc superoxide 
dismutase 1 (SOD1), which accounts for 10-20% of FALS and mostly follow an autosomal 
dominant inheritance pattern(Rosen et al 1994), although an aspartic acid to alanine (D90A) 
point mutation found in the Scandanavian population displays recessive inheritance(Andersen 
2001). Multiple efforts (ClinicalTrials.gov NCT00706147)(Gros-Louis et al 2010; Lange et al 
2013; Miller et al 2005; Miller et al 2013; Patel et al 2014; Ralph et al 2005a; Raoul et al 2005; 
Ray et al 2005; Riboldi et al 2014; Smith et al 2006; Winer et al 2013) have focused on targeted 
therapeutic approaches for SOD1-related ALS (ALS
SOD1
). 
To test the efficacy of SOD1-focused therapeutics, an ALS
SOD1
 natural history dataset is 
required to determine the patient sample size needed to observe the desired effect.  Considering 
the rare nature of SOD1 mutations, these historical control data may also be used in future 
clinical trials provided that updated data show no change in disease measures.  Given the 
heterogeneity among different SOD1 mutations(Cudkowicz et al 1997), it is important to 
clinically stratify mutations in SOD1 according to disease duration and rate of progression.  The 
A4V (SOD1
A4V
) is known for an exceptionally aggressive disease course and relatively low 
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inter-patient clinical variability, and represents about 50% of ALS
SOD1
 in the United 
States(Cudkowicz et al 1997; Rosen et al 1993). 
We report the findings from a multicenter retrospective chart review of genetically-
confirmed ALS
SOD1
 cases cared for after the year 2000 and discuss implications for future 
ALS
SOD1




Data Acquisition  
 We corresponded with 37 sites within the Northeast ALS Consortium Network (NEALS), 
an international, independent, non-profit group of research sites who collaboratively conduct 
ALS clinical research.  Sites performed a retrospective chart review of their respective ALS
SOD1
 
patients cared for from the year 2000 to present.  Data were sent to the coordinating center at the 
Washington University in St. Louis and entered into a central database.  Information for all 
patients was de-identified, and data collection and processing were approved by the local IRB 
committees.  The following 17 centers sent charts as part of this study:  Washington University 
School of Medicine, Northwestern University Feinberg School of Medicine, University of 
Washington Medical Center, Neurology Clinical Research Institute at Massachusetts General 
Hospital, Mayo Clinic Florida, Emory University School of Medicine, Johns Hopkins 
University, Wake Forest School of Medicine, Perelman School of Medicine at the University of 
Pennsylvania, Methodist Neurological Institute at The Methodist Hospital, Neurosciences 
Institute at Albany Medical Center, University of Utah, Sunnybrook Health Sciences Centre, 
University of California Irvine, University of Michigan, University of Kansas Medical Center, 
and Cedars-Sinai Medical Center. 
Data collection and analysis  
All sites received a standardized form with the following items requested: gender, genetic 
mutation, month/year of birth, month/year of symptom onset, month/year of death, month/year of 
permanent ventilation (if applicable), ALS-Functional Rating Scale (ALS-FRS) at time points 
where available, and forced vital capacity (FVC) at time points where available. Symptom onset 
was defined as the first reported loss of function, such as limb weakness or dysarthria.  
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Genetic testing was performed by individual institutions at the time of diagnosis, and 
sites were asked to only report the specific SOD1 mutation found.  Data were collected and 
analyzed from individual patients or families of index cases with confirmed SOD1 mutations 
only; mutations recorded as “self-reported” were not included in the analysis.  All mutations are 
reported in this study using the traditional numbering nomenclature, i.e. not counting the first 
(ATG) codon. When time of onset could not be narrowed down to more than a range of several 
months, e.g. “fall 2011”, the onset was determined to be the midpoint of that range, e.g. “October 
2011.”  Patients still alive at the time of data collection were reported as such, and their last 
recorded FVC or ALS-FRS, whichever came later, was used for survival analyses.  ALS-FRS is 
understood to be the revised scale (ALSFRS-R), a 12-item questionnaire with the highest, 
normal score being 48(Cedarbaum et al 1999).  When both sitting and lying FVC readings were 
available, sitting values were used.  Additional clinical features, such as site of onset and 
presence of non-motor symptoms and signs, were not analyzed in this study.  
Statistical Analysis 
SAS Version 9.3 (Cary, NC) was used to perform all statistical analyses. Descriptive 
statistics were provided for gender, age, and disease duration by mutation group (A4V and Non-
A4V) and total patients, respectively. Additionally, mean, standard deviation of age, and disease 
duration were calculated for each interested mutation. The primary study endpoints included 
ALS-FRS and FVC while secondary endpoint was overall survival (OS). OS was defined as the 
date of symptom onset to death from any cause or last follow-up. Kaplan-Meier (KM) curves for 
OS were generated that provide unadjusted survival estimates for total sample and between 
mutation groups (Non-A4V vs. A4V), respectively. Difference between mutations groups were 
determined by log-rank testing.  
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The study sample includes ALS-FRS and FVC measurements for multiple visits. To 
account for correlations among repeated measures from the same patient, the longitudinal data 
was analyzed using a generalized estimating equation (GEE) model with log link function to 
examine the change in ALS-FRS and FVC measurements over the first three time points 
recorded for a patient. The autoregressive of first order as working correlation structure was used 
and the patients with missing values at any assessment number were excluded from GEE 
analysis. The GEE model includes the group indicator, time points, the interaction term between 
group and time points. The p-values of the interaction term from type 3 analysis in the GEE 
model were estimated to assess whether the measurements across all time points between A4V 
and Non-A4V groups were significantly different. The least square mean and standard error of 




Descriptive Features  
Applicable data were collected from 15 medical centers.  A total of 175 subjects with 
confirmed SOD1 mutations were analyzed. Of subjects collected, 63 had SOD1
A4V
 mutations 
(36.4%), the most common mutation observed in this cohort. 112 subjects had SOD1
Non-A4V
 
mutations (63.6%). There was a slight male dominance in this cohort with a male-female ratio of 





 (1.29:1) subjects (p = 0.9089, Chi-Squared testing) 
(Table 2.1).  
A total of 36 distinct, missense SOD1 mutations were found in this cohort. The most 
common SOD1
Non-A4V 
mutation was I113T (Ile-Thr) in 32 subjects (18.3%), followed by G41D 
(Gly-Asp) (11 subjects; 6.4%), and E40K (Glu-Lys) (10 subjects; 5.7%). The frequencies and 




















No. of subjects (%)  175 (100) 63 (36.4) 112 (63.6)  
Male-Female Ratio 1.30 : 1 1.33 : 1 1.29 : 1 0.91
 
Mean age at onset 
(yr) ± SD (n)  
49.7 ± 12.3 (162) 50.0 ± 12.4 (57) 49.5 ± 12.3 (105) 0.72 
Mean disease duration  
(yr) ± SD (n) 
4.6 ± 6.0  
(134)  
1.4 ± 0.7  
(51) 




Median survival (yr) 2.7 1.2 6.8 <0.0001
 











     
Exon Codon Substitution No. of 
Patients (%) 
Mean Age at Onset 









1 4 Ala-Val 63 (36.6) 49.9 ± 12.3 (57) 1.4 ± 0.7 (51) 1.2 
4 113 Ile-Thr 32 (18.3) 54.2 ± 10.7 (29) 5.3 ± 4.8 (22) 3.3 
2 41 Gly-Asp 11 (6.4) 34.2 ± 7.8 (8) 23.5 ± 14 (4) 21 
4 100 Glu-Lys 10 (5.7) 39.6 ± 5.9 (10) 8.9 ± 5.2 (8)  9.1 
4 100 Glu-Gly 5 (2.9) 42.6 ± 9.1 (5) 9 ± 6.2 (4) 7.2 
4 89 Ala-Val 4 (2.3) 56 ± 10.4 (4) 8 + 1.6 (2) 8 
1 4 Ala-Thr 3 (1.7) 50 ± 10.1 (3) 0.8 ± 0.05 (2) 0.8 
4 90 Asp-Ala 3 (1.7) 57.7 ± 9.6 (3) 9.7 ± 5.4 (2) 9.7 
4 93 Gly-Ala 3 (1.7) 49 ± 12.5 (3) 2.2 ± 0.6 (2) 2.2 
5 137 Thr-Ala 3 (1.7) 38.3 ± 9.2 (3) 9.6 ± 7 (3) 6.4 
1 14 Val-Gly 3 (1.7) 50.3 ± 21.0 (3) 2.6 ± 1 (2) 2.6 
1 6 Cys-Ser 2 (1.2) 54 ± 16.9 (2) 4.1 ± 0.5 (2) 4.1 
5 133
c
 Glu-Ala 2 (1.2) 62 ± 2.8 (2) 0.9 ± 0.6 (2) 0.9 
2 49 Glu-Lys 2 (1.2) 59 ± 19.8 (2) 6.8 ± 1.9 (2) 6.8 





     
Exon Codon Substitution No. of 
Patients (%) 
Mean Age at Onset 









2 37 Gly-Arg 2 (1.2) 26.5 ± 6.4 (2) 7.8  
2 41 Gly-Ala 2 (1.2) 44.5 ± 10.6 (2) 17.3 ± 0 (2) 17.3 
4 85 Gly-Arg 2 (1.2) 56.5 ± 9.2 (2) 2.2 ± 0.3 (2) 2.2 
5 139 Asn-Lys 2 (1.2) 51 ± 2.8 (2) 1.5 ± 0.7 (2) 18.5 
5 148 Val-Gly 2 (1.2) 49.5 ± 0.7 (2) 0.7 ± 0.4 (2) 0.7 
1 4
c
 Ala-His 1 (0.6) 50   
5 125
c
 Asp-Ala 1 (0.6) 63 1.1  
3 76 Asp-Tyr 1 (0.6) 75 3.7  
4 108
c
 Gly-Arg 1 (0.6) 67 1.7  
1 10
c
 Gly-Ala 1 (0.6) 59 4.8  
5 141 Gly-Ala 1 (0.6) 43   
2 37 Gly-Val 1 (0.6) 36 4.6  
2 41 Gly-Ser 1 (0.6) 67 0.4  
4 93 Gly-Ser 1 (0.6) 45   
2 43 His-Arg 1 (0.6) 56 0.3  





     
Exon Codon Substitution No. of 
Patients (%) 
Mean Age at Onset 









5 144 Leu-Phe 1 (0.6) 66 6.2  
5 144 Leu-Ser 1 (0.6) 56 7.8  
1 14 Val-Met 1 (0.6) 54 4.1  
4 87 Val-Met  1 (0.6) 39 8.8  
5 134 Thr-Cys 1(0.6) 55   
 N/A  1 (0.6)    








The mutations are ordered by decreasing number of affected patients. Nomenclature corresponds to 
amino acid sequence excluding ATG start codon.   
b
Censored data are included in determination of mean or median duration 
c
Mutations that are not listed in the ALSoD Database as of 5/5/15 
d
Total number of subjects with available data 
 





Age of Disease Onset  





 patients available for analysis. The mean age of onset for all subjects was 
49.7 ± 12.3 years (mean ± standard deviation). The mean age of onset varied across different 
mutations, with G37R (Gly-Arg) and D133A (Asp-Ala) mutations associated with the youngest 
and oldest mean ages at onset, respectively (Figure 2.1A). There was no significant difference in 
mean age of onset between SOD1
A4V 
(50.0 ± 12.4 years) and SOD1
Non-A4V
 (49.5 ± 12.3 years) 
subjects (p = 0.72, Kruskal-Wallis) (Table 2.1). 
Disease Duration  
 Disease duration information was available for 134 (76.6%) of total subjects, including 
51 SOD1
A4V
 and 83 SOD1
Non-A4V
 patients. The mean disease duration was 4.6 ± 6.0 years for all 
SOD1 subjects, 1.4 ± 0.7 years for SOD1
A4V
 subjects, and 6.6 ± 7.0 years for SOD1
 Non-A4V
 
(Table 2.1). Disease duration varied between mutation type, ranging from rapidly progressing 
mutations such as A4T (Ala-Thr) (0.8 ± 0.1 years) to slow progressing mutants such as G41D 
(Gly-Asp) (23.5 ± 14.0 years) (Figure 2.1B). 
Kaplan-Meier survival analysis was performed comparing the survival probabilities from 




 (Figure 2.2). Of 120 subjects 
analyzed, 35 were SOD1
A4V
 and 85 were SOD1
Non-A4V
. The median survival for all subjects was 
2.7 years, 1.2 years for SOD1
A4V




 median survival was 
significantly shorter than SOD1
Non-A4V
 by log-rank test (p <0.0001). No SOD1
A4V
 subjects 














(A.) The mean age at onset and (B.) mean disease duration were reported for each mutation 
population with a minimum n = 2.  There was no statistical significance between all SOD1 
patients (n =162), SOD1
Non-A4V
 patients (n = 105), SOD1
A4V
 patients (n = 57) (p = 0.7217, 





 mutations associated, respectively, with the youngest and oldest mean ages at onset 





 mutations associated, respectively, with the shortest and 
longest disease durations. SOD1
A4V
 disease duration (n =51) is significantly shorter than 
SOD1
Non-A4V
























 familial ALS 
(A.) Plot for survival probability of all SOD1 mutation patients. 112 subjects were analyzed. The 
median survival for all SOD1 patients is 2.7 years. The survival probabilities for SOD1 patients 
and the corresponding 95% confidence intervals were 0.82 (0.73, 0.88), 0.51 (0.41, 0.60), and 










.  The presence of SOD1
A4V
 mutations was associated with shorter survival 
(p < 0.0001, log-rank).  The survival probability for SOD1
A4V
 patients and the corresponding 
95% confidence intervals were 0.60 (0.41, 0.75), 0.04 (0.00, 0.15), and 0.00 (n/a, n/a) at years 1, 
3 and 5, respectively, after disease onset.  No SOD1
A4V
 patients survived to year 4.  The survival 
probability of SOD1
Non-A4V
 patients was 0.91 (0.82, 0.96), 0.70 (0.59, 0.79), and 0.60 (0.48, 0.71) 
at 1, 3 and 5 years after disease onset. 
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FRS and FVC  
Only three data points were considered for FRS and FVC. 30 SOD1
A4V
 and 75 SOD1
Non-
A4V
 subjects were used for ALS-FRS and FVC analysis. The least mean and standard error of 
ALS-FRS for SOD1
A4V
 were 37.8 ± 1.4, 30.0 ± 2.0, and 22.3 ± 3.7; while those of SOD1
Non-A4V
 
were 35.9 ± 0.9, 32.9 ± 1.1, and 29.9 ± 1.3 at time points 1, 2, and 3, respectively. A statistically 
significant difference was seen in ALS-FRS across three time points in SOD1
A4V
 compared to 
SOD1
Non-A4V
 subjects (p = 0.02, Figure 2.3A). Additionally, 37 SOD1
A4V
 and 81 SOD1
Non-A4V
 
subjects were used for FVC analysis. Dates of permanent ventilation were rarely available (less 
than 5% of total subjects), most likely due to death without receiving tracheal ventilation, and so 
were not included in final analysis. Similarly, a statistically significant increase in ALS-FVC 




 (p = 0.02, Figure 2.3B). The least 
mean and standard error of FVC for SOD1
A4V
 were 86.2 ± 4.1, 58.8 ± 5.1, and 50.7 ± 9.8; while 
those of SOD1
Non-A4V





















(A.) Least squares mean of ALS-FRS over multiple assessment periods. SOD1
A4V
 patients 
decline from mean ALS-FRS 37.6 (35.1, 40.6) (95% CI) at assessment point 1, 29.9 (26.2, 34.3) 
at assessment point 2, to 22.3 (16.1, 31.0) at assessment point 3. SOD1
Non-A4V
 patients decline 
from mean ALS-FRS 35.9 (34.1, 37.8) at assessment point 1, 35.9 (34.1, 37.8) at assessment 
point 2, to 29.9 (27.4, 32.2) at assessment point 3.The SOD1
A4V
 FRS decline is significantly 
increased compared to SOD1
Non-A4V
 (p = 0.0168).  (B.) Least squares mean of FVC over multiple 
assessment periods. SOD1
A4V
 patients decline from mean ALS-FRS 86.2 (78.6, 94.5) (95% CI) 
at assessment point 1, 58.8 (49.6, 69.8) at assessment point 2, to 50.8 (34.8, 74.0) at assessment 
point 3. SOD1
Non-A4V
 patients decline from mean FVC 74.7 (69.5, 80.4) at assessment point 1, 
63.4 (57.5, 69.8) at assessment point 2, to 55.6 (48.4, 64.0) at assessment point 3.The SOD1
A4V
 
FVC decline is significantly increased compared to SOD1
Non-A4V
 (p = 0.0168). Error bars 
represent standard error of the mean (SEM).  
 
 Figure 2.3 SOD1
A4V







We collected data from 15 North American centers, studying 175 subjects with 
confirmed SOD1 mutations, cared for from the year 2000 to present. The number of patients 
available for this study represent the largest effort to study ALS
SOD1
 natural history in almost 20 
years. Combining data from multiple studies(Andersen et al 1997a; Andersen et al 2003; 
Cudkowicz et al 1998; Cudkowicz et al 1997; Gellera et al 2001; Juneja et al 1997; Rosen et al 
1994; Sato et al 2005; Stewart et al 2006) suggests mean disease duration for all SOD1 is 3.9 ± 
5.5 years and SOD1
A4V
 is 1.4 ± 0.9 years.  Three of these studies (Cudkowicz et al 1997; Juneja 
et al 1997; Rosen et al 1994) represent 92% of the 199 reported patients and use data collected 
more than 20 years ago and published in the 1990’s.  Our calculated disease duration for all 
SOD1 of 4.6 ± 6.0 and SOD1
A4V
 of 1.4 ± 0.7 years indicates no significant change in the natural 
history of the disease since these historical data were collected. Our results provide updated 













) accounting for two-thirds of all subjects.  Our 
data show a smaller percentage (36.4%) of SOD1
A4V
 among all ALS
SOD1
 subjects than 
previously reported (50%).  This may reflect the recent expansion in genetic testing and 
improvement of ALS care, leading to increased detection of SOD1 mutations with less 
aggressive or typical presentations.  Interestingly, male predominance was present, although 
mild, in ALS
SOD1
 subjects as a whole (M:F of 1.3).  These findings may reflect potential bias in 
the dataset, as they are in contrast to a recent literature review (McCombe & Henderson 2010). 
However, ALS
SOD1
 cohorts published earlier report similar male predominance (Cudkowicz et al 
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1997). Age of onset for all SOD1 patients (49.7 ± 12.3 years) was not statistically different from 
SOD1
A4V
 age of onset (50.0 ± 12.4 years), which might be unexpected due to the aggressive 
nature of SOD1
A4V
.  However, these findings are consistent with previous reports (Cudkowicz et 
al 1997) in which onset is similar between SOD1
A4V
 and all SOD1 patients, while progression is 
more rapid in the SOD1
A4V
 population. 
Our results are limited by the design of this study as retrospective. As with all 
retrospective studies, inherent biases exist based upon the availability of data collected. Of the 
original 37 NEALS medical centers which we corresponded, 17 participated in this study. No 
obvious variables such as geographic location or size of center were linked to the 20 medical 
centers that did not respond. Correspondingly, data included in the study have come from clinical 
centers spanning wide geographical regions and likely capture a significant portion of the 
ALS
SOD1
 population in North America. However, assumptions must be made when compiling 
survival data from multiple centers, including consistency of standard of care. Also, given that 
our data were drawn from large ALS referral centers, survival and progression rate numbers may 
be different than outcomes in the community.  
Natural history data is optimally collected prospectively, and in fact a portion of our data 
from 2013-2014 was collected as such. Efforts to collect prospective natural history data on 
ALS
SOD1
, and FALS in general, should be considered in the future and will be better able to 
capture real-time clinical information, such as site of onset and presence of extra-motor findings, 
in addition to more closely documenting paraclinical endpoints such as ALS-FRS, FVC and 
time-to-permanent-ventilation. Despite these limitations, the rarity of ALS
SOD1
 coupled with the 
urgent need for enabling new clinical trials helps justify the use of a retrospective study design.   
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  In clinical trials with a rare disease population, such as ALS
SOD1
, historical controls may 
be implemented to assess outcomes. As recruitment of patients to a trial in a rare disease 
population is challenging, the use of historical controls would be valuable to design an 
adequately-powered trail. However, it is important to validate if historical data has changed over 
time.  In contrast to our results focusing on ALS
SOD1
, previous natural history studies (Czaplinski 
et al 2006b; Qureshi et al 2009) of the ALS population suggest an increase in survival and 
conclude this may reflect improvement in respiratory, nutritional and supportive clinical care.  
These findings may suggest that, although overall ALS survival has improved over time, 
ALS
SOD1
 may represent a unique ALS subpopulation. Although our data suggests the ALS
SOD1
 
has not changed over time, the use of historical controls in clinical trials is challenging, and key 
limitations exist in our data for direct implementation as historical controls. To properly match 
patients in trials with historical controls, additional data such as standard of care (riluzole use, 
non-invasive ventilation), cognitive status, and site of disease onset must be collected, leading to 
enhanced comparisons with a future cohort. Future prospective studies will focus on these 
missing data in future prospective natural history studies in ALS
SOD1
 or other ALS disease 
populations. Nevertheless, the data reported regarding updated survival statistics for this 
population are one important consideration in the use of historical controls. 
The first reported cause of FALS was a mutation in SOD1, and it is now widely accepted 
that the pathogenesis of mutations in SOD1 is related to a gain of toxic function of the SOD1 
protein.  Therefore, global reduction of toxic SOD1 in ALS has been recognized as a possible 
therapeutic intervention. Our work with SOD1 antisense oligonucleotides (Crisp et al 2015; 
Miller et al 2005; Miller et al 2013; Smith et al 2006; Winer et al 2013) and others 
(ClinicalTrials.gov NCT00706147, (Gros-Louis et al 2010; Lange et al 2013; Patel et al 2014; 
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Ralph et al 2005a; Raoul et al 2005; Ray et al 2005; Riboldi et al 2014) have focused on targeted 
SOD1-lowering therapeutics approaches for ALS
SOD1
. Given the heterogeneity of disease 
progression in different mutation carriers, one may envision the design of a trial that stratifies 
results from patients with rapidly progressing disease as defined by unchanged natural history 
data. For example, our analysis of the SOD1
A4V
 patient population in this study suggests that 
SOD1
A4V
 disease characteristics are homogeneous, and natural history has remained unchanged 
over time with a median survival of 1.2 years.  As SOD1
A4V
 is the most common mutation found 
in North America, recruitment for a SOD1
A4V
-focused trial for therapeutic efficacy may be 
feasible.  Assuming an accrual interval of 1 year and additional follow-up interval of 2 years, 52 
SOD1
A4V
 subjects per group (new treatment and placebo) are needed to achieve at least 80% 
power at a 0.05 significance level to detect the statistical difference when the median survival in 
the treatment group is 2.4 years using two-sided log-rank test, where hazard ratio of new 
treatment to control is 0.5.  In contrast, our findings suggest that the median survival in all SOD1 
subjects is 2.7 years, and thus 88 SOD1 subjects per group (new treatment and placebo) are 
needed when the median survival probability in the treatment group is 5.4 years, where hazard 
ratio of new treatment to control is 0.5.  Although the effect sizes discussed here are large, we 
believe such a result is feasible, as SOD1 antisense oligonucleotides directly inhibit the cause of 
motor neuron toxicity and death in ALS
SOD1
.  The prior Phase I trial using SOD1 antisense 
oligonucleotides (Miller et al 2013) in this same population recruited 21 unique patients, 
suggesting that such a trial is feasible. 
 Overall, the data presented here will help guide clinical trial design and may serve as a 
historical control database for ALS
SOD1
 interventional trials, with the hope of demonstrating that 
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Chapter 3: Characterizing SOD1 Protein Kinetics in the 





Autosomal dominant mutations in SOD1 were the first reported genetic cause of ALS 
(Rosen et al 1993). Accumulating evidence suggests that a gain of toxicity function associated 
with the pathological misfolding of mutant SOD1 protein results in the death of motor neurons 
(Ilieva et al 2009). In vitro characterization of mutant, recombinant SOD1 supports this 
hypothesis, as data suggest that the altered stability of mutant SOD1 proteins correlates with 
faster disease progression (Pratt et al 2014; Shi et al 2016). However, the ability to effectively 
analyze pathological SOD1 behavior in the central nervous system (CNS) of living, human 
patients remains elusive, limiting the ability to confirm the biological relevance of in vitro 
observations to ALS prognosis. 
 A key biochemical characteristic of mutant SOD1 protein cell culture (Borchelt et al 
1994) and in vivo (Farr et al 2011) is accelerated turnover caused by protein instability compared 
to wild-type (WT) SOD1. Our group also demonstrated that mutant G93A SOD1 protein exhibits 
faster protein turnover, indicated by a shortened protein half-life, compared with WT SOD1 
protein in the CNS of transgenic rat models. Moreover, misfolded G93A SOD1 protein displayed 
a shorter half-life than the total G93A SOD1 protein pool. These observed effects in the brain 
and spinal cord were mirrored in the CSF of these animals, suggesting that measures of protein 
turnover within CSF are a sufficient proxy for CNS protein biology (Crisp et al 2015). Therefore, 
differences in mutant and WT SOD1 half-life in CSF may provide insight into the identification 
of misfolded SOD1 within the CNS of ALS patients for the first time.   
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 Outside of ALS
SOD1
, the role of SOD1 in sporadic ALS is controversial. In post-mortem 
studies, multiple groups reported misfolded SOD1 in sporadic ALS spinal cord autopsies (Bosco 
et al 2010; Forsberg et al 2010). However, others are unable to reproduce these results (Da Cruz 
et al 2017). These findings have direct therapeutic implications, as SOD1-targeting therapies are 
currently under development for the treatment of ALS
SOD1 
(Benatar et al 2018; Miller et al 2013), 
but only ~2% of the ALS population carry SOD1 mutations. Further data that supports a 
biological role for pathological, misfolded SOD1 in sporadic ALS would be an important finding 
to broaden the utility of targeting SOD1 for therapeutic intervention in the 90% of ALS patients 
with no genetic causes (Kiernan et al 2011).  
 We previously calculated the half-life of CSF SOD1 in normal, health human subjects as 
~25 days using stable isotope labeling kinetics (SILK) analysis via tandem liquid 
chromatography-mass spectrometry (LC-MS/MS) (Crisp et al 2015). In these studies, we 
administered 
13
C6-Leucine via the drinking water of participants fed a low leucine diet. However, 
feedback from healthy control participants suggested dissatisfaction with this method of labeling. 
Considering ALS patients already exhibit a compromised quality of life, it is imperative to 
design clinical studies that ease the burden on the participant population, while still capturing 
accurate measures protein turnover.  
 Here, we performed a preliminary analysis of an ongoing, multicenter study 
(NCT03449212) to determine SOD1 protein half-life in ALS patients. In this study, we wish to 
test the hypothesis that CSF SOD1 kinetics is altered in ALS by comparing: 1. Total SOD1 
protein turnover between ALS participants and healthy controls, and 2. Mutant versus WT SOD1 
protein turnover within ALS participants with SOD1 mutations. To improve participant 
satisfaction, we employed a modified protocol to deliver 
13
C6-Leucine via intravenous infusion 
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to patients over a 16 hour labeling period, and compared results to our previous 10 day oral 
labeling paradigm data. In addition to understanding ALS pathobiology, calculating CSF SOD1 
half-life will also be a key parameter to model pharmacokinetic-pharmacodynamics (PK-PD) 





Human Subjects  
This study involving human subjects was approved by the Washington University Human 
Studies Committee and the Clinical Research Unit (CRU) Advisory Committee (an Institute of 
Clinical and Translational Sciences (ICTS) Resource Unit) and the Institutional Review Board of 
the Partners Human Research Committee at Massachusetts General Hospital. Written informed 
consent was obtained from all participants prior to inclusion in the study.  
  The study population consists of subjects with: known SOD1 positive ALS status, SOD1 
positive carriers without ALS, known C9ORF72 positive ALS status, C9ORF72 positive carriers 
without ALS, sporadic ALS, and non-ALS (normal controls). Inclusion criteria includes (with 
exceptions for each subgroup): males or females aged 18 years or older, positive for SOD1 
mutation, positive for C9ORF72 repeat expansion, diagnosis of definite, probable, or possible 
ALS in accordance with El Escorial Criteria (ALS only) (Westeneng et al 2018), able to hold 
position and breathe comfortably for duration of lumbar puncture procedure. Exclusion criteria 
for all groups include: invasive ventilator dependence, medical inability to undergo lumbar 
puncture, any active dermatologic disease, any connective tissue disease, any known or 
suspected abnormal CSF pressure or intracranial/intraspinal tumors, use of anticoagulant 
medication that cannot be safely withheld until coagulation parameters have normalized prior to 
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lumbar puncture and for up to a week following the lumbar puncture, blood dyscrasia, abnormal 
bleeding diathesis, the use of dialysis for renal failure, safety lab values greater than 2X the 
upper limit of normal, allergy to lidocaine, pregnancy, or any contradiction for lumbar puncture. 
 
13
C6-Leucine Administration and Sample Collection 
Participants were admitted to the Clinical Research Unit (Center for Applied Research 
Sciences, Washington University), received a low-leucine diet (Washington University Research 
Kitchen), and administered an intravenous infusion of 10 g 
13
C6-leucine (Cambridge Isotope 
Laboratories CLM-2262, Cambridge, MA) at a rate between 4 – 10 mg/kg/hr dependent on the 
participant’s weight for 16 hours. Venous blood draws were collected at designated time points 
during the infusion period. CSF, venous blood, and urine were collected over five follow up 
lumbar punctures (LPs) from day 8 after infusion through day 120.  
Participants from Massachusetts General Hospital and select participants from 
Washington University received 10 g of 
13
C6-Leucine via the oral labeling method described 
previously(Crisp et al 2015). Briefly, participants consumed 
13
C6-leucine after dissolving 330 mg 
13
C6-leucine in 120 mL of tap water + Kool-Aid® flavored powder three times per day (total 
daily dose = 990 mg) for 10 days. Overnight fasting blood was collected at day 1, 4, 8, and 10 of 
the 
13
C6-leucine labeling period. CSF via lumbar puncture and venous samples were collected at 
four designated time points between 14-85 days after 
13
C6-leucine labeling was initiated.    
Blood was centrifuged at 1000xg for 10 minutes at room temperature, and 500 uL plasma 
was aliquoted into low-binding 1.7 mL tubes (Axygen, MCT-175-L-C) and frozen on dry ice. 
CSF (20-25 mL) was centrifuged at 1000xg for 10 minutes at 4°C, and 1 mL aliquots were 
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frozen on dry ice. Urine (10 mL) was divided into 1 mL aliquots and frozen on dry ice. All 
samples were stored at -80°C before use. 
Isolation and mass spectrometric analysis of CSF SOD1, free 
13
C6-Leucine in CSF and Plasma, 
and 
13
C6-Leucine labeled total protein  
SOD1 was immunoprecipitated from 1 mL of CSF using 50 uL of M-270 Epoxy 
Dynabeads (Invitrogen, Carlsbad, CA) coupled to anti-SOD1 (mouse monoclonal; Millipore 
Sigma S2147, Burlington, MA) supplemented with 0.1% Tween-20 and protease inhibitors for 2 
hours at room temperature. Before immunoprecipitation, 100 ng of N15-labeled recombinant 
SOD1 (ProSpec-Tany Technogene, Rehovot, Israel) was added to each sample. In SOD1 mutant 
carriers, an additional 50 ng of mutant recombinant SOD1 was added to each sample. Protein 
samples were washed with 25 mM ammonium bicarbonate, reduced with DL-Dithiothreitol in 
100 mM triethylammonium bicarbonate for 30 minutes at 37°C, alkylated with iodoacetamide 
for 30 minutes at RT in the dark, and washed two times with 25 mM ammonium bicarbonate. 
SOD1 was eluted from magnetic beads using 50 uL of formic acid. The formic acid eluent was 
transferred to a new tube and lyophilized via speed vacuum (Labconco, CentriVap), washed with 
100 uL methanol, and lyophilized again via speed vacuum. Dry samples were resuspended in 20 
uL of 50 mM triethylammounium bicarbonate, pH 8.8.  
Proteolytic digestion was performed on resuspended samples with either 600 ng of 
Endoproteinase GluC (Millipore Sigma 11047817001) at 25°C for 16 hours, or a combination 
digest with 250 ng LysC (Millipore Sigma 11047825001) at 37°C for 6 hours followed by 250 
ng Trypsin (Millipore Sigma 11418475001) at 37°C for 12 hours. Samples were desalted and 
washed with TopTipC18 10-200 uL Tip-Columns (Glygen TT2C18.96, Columbia, MD), 
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lyophilized via speed vacuum, and resuspended in 25 uL of 2% acetonitrile/0.1% formic acid 





C6-Leucine tracer-to-tracee ratio (TTR) of SOD1 peptides was 
quantified by comparing the area under the curves for each peptide in the presence or absence of 
13
C6-Leucine. SOD1 TTR measurements were calibrated using a 
13
C6-leucine labeled SOD1 
standard curve derived from HEK cell lysates, as described previously (Crisp et al 2015). SOD1 
protein concentration was quantified by comparing the area under the curve of CSF SOD1 
peptide to the recombinant, N15-labeled peptide (N14-SOD1:N15-SOD1), and calibrated to a 
recombinant SOD1 protein standard curve. See Supplementary Tables 1 and 2 for a summary of 
peptides analyzed.  
 Plasma free, plasma protein-bound, and CSF protein-bound 
13
C6-leucine was determined 
by precipitation of proteins with 10% tricholoroacetic acid overnight at 4°C, followed by 
capillary chromatography-negative chemical ionization-quadrupole-mass spectrometry (Agilent 
6890N Gas Chromatograph and Agilent 5973N Mass Selective Detector) as described previously 
(Potter et al 2013). 
Compartmental Modeling 
Modeling was conducted using SAAM II (The Epsilon Group, Charlottesville, NC). 
Kinetic data for plasma free 
13
C6-leucine, CSF total protein, plasma total protein, and CSF SOD1 
species for each subject were incorporated into a compartmental model that uses the shape of the 
plasma leucine enrichment time course as a “front end” to describe the enrichment time course 
shapes for the product proteins (Supplemental Figure 1).  Each protein (CSF SOD1, CSF total 
protein, and plasma total protein) is assumed to be at steady state over the ~120 day time course.   
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The total rate of production of each protein was thus assumed to be constant over time, but the 
rate at which isotopically labeled protein is synthesized was dependent on the mole fraction of 
isotopically labeled plasma leucine monitored over the ~120 day period. The model describes the 
turnover of each protein as unlabeled protein is initially replaced with labeled protein, and then 
labeled protein is cleared and replaced with unlabeled protein. It was necessary to assume that 
each protein was kinetically heterogeneous, consisting of a mixture of faster and slower turning 
over components, in order to optimally fit the shapes of each protein enrichment time course. In 
addition, the slower component of SOD1 was optimally described as a minimal 2-compartment 
delay chain, i.e. two compartments in series. All CSF SOD1 peptides analyzed were used as 
individual replicates at each time point for modeling. All TTR values were converted to mole-
fraction label (MFL) for modeling using the following equation: 
 
Modeling results are reported as fractional turnover rates (FTR, pools/d; the fraction of the pool 
turning over per day) and an estimate of the error (reported as a coefficient of variation) for each. 
Protein half-life was then calculated by the following equation: 
 
Statistical Analysis 
 All quantitative results are expressed as mean ± standard deviation. Due to low sample 





Participant Demographics  
 To date, 12 individual participants initiated the protocol (Table 3.1). Of these, 1 
participant withdrew from the study due to complications associated with the lumbar puncture 
procedure, resulting in a current study completion rate of over 90% (11/12).   The mean 
participant age was 54.5 ± 9.5 years, and the majority of participants were male (75%, 9/12) and 
Caucasian (92%, 11/12). Of the 11 participants analyzed, 1 received the 10 day oral labeling 
protocol of 
13
C6-Leucine, while the remaining received a 16 hour IV infusion of 
13
C6-Leucine.   
Protein Kinetics in Participants via 16 hour, 
13
C6-Leucine intravenous infusion  
 We employed a labeling protocol where we administered 10g of 
13
C6-Leucine via IV 
infusion over a 16-h time period, with subsequent blood draws up to 24 hours from label 
administration. An example of the tracer kinetics observed for participants with this protocol is 
seen in Figure 3.1. Over the five time points between 7 – 120 days when we collected CSF, 
maximum 
13
C6-Leucine enrichment in CSF total protein and SOD1 approaches ~1% and decays 
over time (Figure 3.1B). Calculations of CSF SOD1 half-life in normal, healthy controls by 
compartmental modeling confirmed CSF SOD1 is a long-lived protein, with half-life on the 
order of weeks. This is similar to our previous calculations with the 10 day oral labeling method 
(Figure 3.1B, Table 3.2). We also calculated the half-life of CSF total protein on order of 
weeks, which is similar to previous measures of the predominant protein found in human CSF- 
human serum albumin (half-life of 15-20 days) (Iwao et al 2006). Taken together, these data 




Participant Disease Type Disease Stage 
Labeling 
Method 
Age Race Gender 
Control 1 
  
16 hour IV 60 Caucasian Female 
Control 2 
  
16 hour IV 51 Caucasian Male 
Control 3 
  




ALS 1 SOD1 (A89V) Symptomatic 10 day oral 48 Caucasian Male 
ALS 2 SOD1 (E100K) Symptomatic 16 hour IV 49 Caucasian Male 
ALS 3 SOD1 (A4V) Asymptomatic 16 hour IV 52 Caucasian Male 
  ALS 4* SOD1 (A4V) Asymptomatic 10 day oral 37 Caucasian  Male 
ALS 5 Sporadic Symptomatic 16 hour IV 64 Caucasian Male 
ALS 6 Sporadic Symptomatic 16 hour IV 62 Caucasian Male 
ALS 7 Sporadic Symptomatic 16 hour IV 56 Caucasian Male 
ALS 8 C9ORF72 Symptomatic 16 hour IV 69 Caucasian Female 
ALS 9 C9ORF72 Asymptomatic 16 hour IV 63 Caucasian Male 
   * Participant withdrew from study after first lumbar puncture 
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Figure 3.1. Representative Kinetic Curve of a participant labeled with 10 g 
13
C6-Leucine 
via 16 hour intravenous infusion. 
(A.) 
13
C6-Leucine plasma enrichment during the first 24 hours of procedure. Peak 
13
C6-Leucine 
enrichment in plasma free leucine is observed at end of 16 hour labeling period near 40% of total 
leucine pool, with rapid clearance of 
13
C6-leucine maximum incorporation into plasma protein 
observed within the first 8 hours of the chase period. (B.) 
13
C6-Leucine enrichment in CSF and 
plasma proteins over time. Representative protein half-life values (t1/2) calculated from 
compartmental modeling corresponds to participant Control 1.  
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Total CSF SOD1 Behavior in ALS 
 To analyze total CSF SOD1 protein behavior in ALS, we categorized participants into 
four groups: SOD1 mutation carriers, sporadic ALS, C9ORF72 repeat expansion carriers, and 
healthy controls (Table 3.2).  In addition to ALS
SOD1
 and sporadic ALS groups, analyzing CSF 
SOD1 protein in the C9ORF72 group serves as a negative control to test for specificity of altered 
SOD1 behavior, as SOD1 pathology is not implicated in the C9ORF72 disease population. 
Finally, the healthy control group serves as a control to identify differences in SOD1 protein 
behavior due to disease pathology. At this time, the sample sizes of these individual subgroup are 
not sufficient to determine any statistically significant differences between the groups (n = 2 – 3 
per group). 
 Normal control subjects had an average CSF SOD1 protein concentration of 164.7  11.2 
ng/mL, with an average CSF SOD1 protein half-life of 20.6  8.5 days. The ALS groups (SOD1, 
sporadic, and C9ORF72) appear to show elevated CSF SOD1 concentration compared with 
normal controls, ranging from 191.0  6.5 ng/mL (C9ORF72) to 270.5  62.5 ng/mL (SOD1). 
Moreover, average CSF SOD1 half-life in ALS groups ranged between 25.0  7.1 (sporadic) to – 
29.3  20.2 days (SOD1). Due to the variable nature and small sample size in these groups, no 
we cannot draw definitive conclusions that suggest there are clear changes in in total CSF SOD1 







CSF SOD1  CSF Protein  Plasma Protein 
Group 
Concentration 
(ng/mL ± SD) 
Half-Life        
(Days ± SD)  
Half-Life         
(Days ± SD)  
Half-Life            
(Days ± SD) 
SOD1* 
(n=3) 





247.9 ± 98.7 25.0 ± 7.1  29.3 ± 0.7  4.1 ± 0.7 
C9ORF72
&
 (n= 2) 




(n = 3) 
164.7 ± 11.2 20.6 ± 8.5  22.7 ± 6.1  4.8 ± 1.0 
* Participants with confirmed SOD1 mutations (ALS 1, ALS 2, ALS 3) 
+ Symptomatic ALS participants without identified mutations (ALS 5, 6, 7) 
& Participants with confirmed hexanucleotide repeat expansion in the C9ORF72 gene (ALS 8, ALS9) 
# Healthy participants without neurological disease (Control 1, Control 2, Control 3) 














Mutant versus Wild-Type CSF SOD1 in SOD1 Mutation Carriers  
 Previous efforts to characterize CSF SOD1 protein concentration and turnover analyzed 
the entire SOD1 protein pool. However, three participants had genetically confirmed point 
mutations in the SOD1 gene with a familial history of disease (Table 3.1). These individuals 
carry one copy of the mutant SOD1 gene, and one copy of WT SOD1, and an advantage of our 
mass spectrometry-based SILK analysis is the ability to distinguish these two proteins within 
CSF. Thus, we are able to test hypotheses related to differential behavior in both forms of the 
protein with regards to SOD1 protein concentration and half-life.  Two participants were 
previously diagnosed with ALS and were similar in age (48 and 49 years old). Interestingly, 
natural history data suggests the median disease duration in these two mutant SOD1 carriers is 
similar (A89V median survival: 8 years, E100K median survival: 9.1 years, (Bali et al 2017)). 
An additional participant carried an A4V mutation, the most common mutation in the North 
American population, with rapidly aggressive disease progression (median survival: 1.2 years 
(Bali et al 2017)). 
 Average WT CSF SOD1 protein concentration ranged from 96.4 ng/mL to 214.4 ng/mL 
in participants (Table 3.3). In symptomatic participants carrying A89V and E100K mutations, 
the concentration of mutant CSF SOD1 protein appeared elevated relative to WT CSF SOD1, 
while the half-life of mutant and WT CSF SOD1 were similar within each individual patient. 
Contrary to these findings, the asymptomatic participant carrying an A4V mutation showed a ~9-
fold decrease in mutant CSF SOD1 concentration. Due to limitations in instrument sensitivity, 
SOD1 A4V half-life could not be calculated. These discrepancies appear to be independent from 
global changes in protein metabolism, as the plasma total protein half-life is similar between all 
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patients (Table 3.3). Thus, these data suggest that different SOD1 mutations may exhibit 



































ALS 1 A89V 137.7 26.3  205 25.7 
ALS 2 E100K 96.4 31.6  135.4 28.8 
ALS 3 A4V 214 25.3  23.6 - 
 





These data provide the first insight into SOD1 protein kinetics in the central nervous system 
of patients with ALS. Although limited in overall interpretation due to small sample size, this 
preliminary analysis provides a foundation for future data interpretation when the remaining 15 
currently enrolled and future participants complete this study. To our knowledge, this study is 
also the first examination of mutant versus WT protein kinetics in an autosomal dominant 
neurological disorder. These findings are valuable to understand disease pathobiology in human 
ALS. Further, these data also provide crucial values for parameters in randomized control 
clinical trial design to test new for this devastating disease.     
Our previous efforts to calculate SOD1 protein half-life in human CSF employed an oral 
labeling method with 
13
C6-Leucine (Crisp et al 2015). However, the 16-hour infusion protocol 
described here provides multiple advantages over an oral labeling paradigm for tracer-based 
kinetic analysis. From an analytical perspective, our IV protocol allows for a higher sampling of 
plasma leucine time points during the 
13
C6-Leucine labeling period, as previous measurements of 
13
C6-Leucine input into plasma were sampled with 2-3 blood draws over a 10-day period. This 
higher sampling frequency limits the variance in tracer input modeling, improving the quality of 
fit of the model to data. Our kinetic analysis calculated CSF total protein half-life on the order of 
20-30 days, which is relatively similar to the previously half-life of human serum albumin, the 
predominant protein found in Human CSF, between 15-20 days (Iwao et al 2006). Importantly, 
the 16 hour IV protocol is less burdensome for patients compared to adhering to a strict diet and 
self-administered labeling paradigm over a 10 day labeling period.  Therefore, controlled 
administration of 
13
C6-Leucine with IV infusion may limits variability in study compliance and 
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improves the overall participant experience in an already invasive clinical study associated with 
multiple lumbar punctures.  
Calculations of SOD1 protein half-life are directly applicable to current clinical trials in ALS, 
as multiple experimental therapeutics target SOD1 by inhibiting protein synthesis (Lange et al ; 
Miller et al 2013) or promoting protein degradation (Benatar et al 2018). For example, Antisense 
Oligonucleotides that target SOD1 mRNA for degradation rely on measures of CSF SOD1 
protein concentration as a biomarker to assay target engagement of ASO with SOD1 mRNA in 
the central nervous system of patients (Winer et al 2013). However, decreases in CSF SOD1 
protein concentration also rely on clearance of SOD1 protein that is unaffected by ASO 
treatment, and this rate of protein clearance is determined by protein half-life. Therefore, our 
calculations of CSF SOD1 half-life as ~25 days here and in previous work (Crisp et al 2015) 
establish a critical parameter to understand the relationship between SOD1 ASO treatment and 
maximum lowering of CSF SOD1 protein concentration (Figure 3.2). 
Our preliminary results show similar values of total SOD1 protein half-life between 
participants with SOD1 mutations and controls. However, comparison of mutant versus WT 
SOD1 protein in an A4V SOD1 participant suggests that A4V SOD1 protein exhibits altered 
protein behavior compared to WT SOD1. An attractive hypothesis to explain this phenomenon is 
that SOD1 half-life correlates to the overall stability of the protein, suggesting that alterations in 
protein half-life indicate protein misfolding. Indeed, these results have been observed with 
different SOD1 mutants in cell culture (Borchelt et al 1994), and measures of mutant SOD1 
protein stability in patient red blood cells appear to correlate with rate of disease progression 
(Sato et al 2005). Interestingly, the half-life of E100K and A89V SOD1 in two participants 
showed similar measures of protein half-life to WT SOD1, suggesting mutant-specific 
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differences in SOD1 kinetics between ALS participants. However, the small sample size of this 
experiment, combined with an inability to confirm the misfolded state of CSF SOD1 protein 
leaves any interpretation of these results at this stage to be speculative. Our mass spectrometry-
based approach has multiple advantage for future studies, as we are able to interrogate multiple 
forms of SOD1 protein within a sample. In addition to distinguishing mutant versus WT SOD1 
protein, future investigation should also search for posttranslational modifications of CSF SOD1 
that have been implicated in forms of pathological SOD1, such as deamidation (Schmitt & Agar 
2017), SUMOylation (Niikura et al 2014), and disulfide reduction (Bosco et al 2010; Nagano et 
al 2015; Tiwari & Hayward 2003).  
Similar efforts to analyzed CSF SOD1 half-life can be employed to investigate the potential 
role of SOD1 in sporadic ALS. Such data will contribute to resolving the controversial 
identification of misfolded, WT SOD1 in post-mortem tissue sections (Bosco et al 2010; Da 
Cruz et al 2017; Kerman et al 2010) or by CSF ELISA (Zetterstrom et al 2011). An important 
consideration in developing experiments to identify changes in CSF SOD1 protein behavior is to 
ensure that alterations in CSF SOD1 protein concentration or half-life are specific to sporadic 
ALS. For example, Zetterstrom and colleagues failed to distinguish differences in misfolded 
SOD1 between ALS patients and normal controls, questioning the validity of their misfolded 
SOD1 ELISA. To help control for changes observed in CSF SOD1 protein in sporadic ALS, 
future studies will also measure CSF SOD1 concentration and half-life in other neurological 
disease states, such as Alzheimer’s Disease and Parkinson’s Disease. These participants will help 
to control for any effects observed due to overall neurodegeneration. An additional consideration 
is the overall variance in CNS protein metabolism individual subjects. Thus, incorporation of 
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Figure 3.2 Theoretical modeling of CSF SOD1 protein levels after ASO treatment. 
Indirect response model used to simulate SOD1 protein levels after 4 doses of SOD1 antisense 




Where Kin = 1, Kout = SOD1 half-life (25 days), IC50 = 10, and Cp is the SOD1 ASO 
concentration. SOD1 protein concentrations were normalized to % of initial value.  Drug (SOD1 
Antisense Oligonucleotide) tissue concentrations simulated after 4 bolus doses administered on 
Days 0, 28, 56, and 84. Assumed drug t1/2 = 30 days.  
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apolipoprotein E (Wildsmith et al 2012), and alpha synuclein (Fanara et al 2012) will provide 
valuable information to distinguish the specificity of SOD1 changes in protein turnover for ALS 
participants. These data will provide valuable information for the field to determine the utility of 
SOD1-targeting therapeutics in the remaining 98% of ALS patients without SOD1 mutations. 
In sum, our work characterizing CSF SOD1 half-life will lead to a better understanding of 
ALS biology, while also helping to optimize clinical trial design advance SOD1-targeted 
therapies through the therapeutic pipeline for ALS.  
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Supplementary Figure 3.1 Compartmental model for kinetic data using plasma free 
13
C6-
Leucine (input), CSF total protein, plasma total protein, and CSF SOD1 species for each 
















 +++ WT 557.9737 547.3086 35 19 
    
707.4087 35 14 
    
735.9194 35 14 
    
804.4462 35 14 
  
13
C6-Leu 559.9804 553.3287 35 19 
    
710.4187 35 14 
    
738.9294 35 14 
    
810.4663 35 14 
  
N15 564.6206 553.2908 35 19 
    
715.3849 35 14 
    
744.3942 35 14 
    




 ++ WT 516.7541 308.1717 35 13 
    
649.3205 35 18 
    
725.3365 35 18 
    
748.3889 35 18 
  
13
C6-Leu 519.7642 314.1918 35 13 
    
655.3406 35 18 
    
725.3365 35 18 
    
754.409 35 18 
  
N15 524.2319 313.1569 35 13 
    
659.2909 35 18 
    
735.3069 35 18 
    




 +++ WT 756.3803 425.2199 35 26 
    
474.7541 35 26 
    
565.2841 35 31 
    
910.9479 35 21 
  
13
C6-Leu 758.387 428.23 35 26 
    
477.7642 35 26 
    
565.2841 35 31 
    
913.958 35 21 
  
N15 766.0183 432.1992 35 26 
    
482.2319 35 26 
    
575.2545 35 31 
    




 +++ WT 769.7302 302.1347 35 26 
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846.9279 35 21 
    
946.986 35 21 
    
1003.528 35 21 
  
13
C6-Leu 771.7369 846.9279 35 21 
    
849.938 35 21 
    
949.9961 35 21 
    
1006.5381 35 21 
  
N15 779.0359 305.1258 35 26 
    
857.8953 35 21 
    
958.9504 35 21 
    




 ++ WT 616.7913 315.1663 35 22 
    
430.1932 35 22 
    
690.3053 35 22 
    
803.3894 35 22 
  
13
C6-Leu 619.8014 315.1663 35 22 
    
430.1932 35 22 
    
690.3053 35 22 
    
809.4095 35 22 
  
N15 624.2691 319.1544 35 22 
   
624.2691 435.1784 35 22 
   
624.2691 699.2786 35 22 
   




 +++ WT 654.3459 681.3331 35 22 
    
730.8674 35 22 
    
815.9201 35 17 
    
872.4622 35 17 
  
13
C6-Leu 656.3527 684.3432 35 22 
    
733.8774 35 22 
    
818.9302 35 17 
    
875.4722 35 17 
  
N15 662.9869 690.805 35 22 
    
740.8377 35 22 
    
826.8875 35 17 
    
883.9281 35 17 
 
Supplementary Table 3.1 Transition ions used for SOD1 tandem liquid chromatography-
























519.2959 35 10 
 
 








525.3161 35 10 
 
 





























817.4414 35 22 
  
  
989.4948 35 22 
 
 




















995.5099 35 22 
 
 








































611.3511 35 14 
 
 
















611.3511 35 14 
 
 
N15 418.2303 279.1465 35 14 
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618.3643 35 14 
 
 








624.3845 35 14 
 
 












 ++ A89V 627.3279 361.2082 32 22 
    
462.2558 32 22 
    
561.3243 32 22 
    
675.3672 32 22 
    
845.4727 32 22 
    
1017.5211 32 22 
  
13C6-Leu 630.3379 361.2082 32 22 
    
462.2558 32 22 
    
561.3243 32 22 
    
675.3672 32 22 
    
851.4928 32 22 
    
1023.5412 32 22 
  
N15 635.3041 365.1963 32 22 
    
467.241 32 22 
    
567.3065 32 22 
    
683.3435 32 22 
    
855.4431 32 22 
    




 +++ E100K 543.6069 507.7429 28 14 
    
607.801 28 14 
    
664.343 28 16 
    
713.8772 28 14 
  
13C6-Leu 545.6136 507.7429 28 14 
    
610.811 28 14 
    
667.3531 28 16 
    
716.8873 28 14 
  
N15 550.2538 514.7222 28 14 
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615.7772 28 16 
    
672.8178 28 14 
    
722.8505 28 14 
 
Supplementary Table 3.2 Transition ions used for SOD1 tandem liquid chromatography-

















Clinical trials for progressive neurodegenerative disorders such as Alzheimer’s Disease 
and Amyotrophic Lateral Sclerosis have been hindered due to the absence of effective 
pharmacodynamics markers to assay target engagement. We tested whether measurements of 
new protein production would be a viable pharmacodynamics tool for RNA-targeted therapies. 
To test this hypothesis, transgenic animal models expressing human proteins implicated in 
neurodegenerative disorders -- microtubule-associated protein tau (hTau) or superoxide 
dismutase-1 (hSOD1) -- were treated with antisense oligonucleotides (ASOs) delivered to the 
central nervous system to target these human mRNA transcripts. Simultaneously, animals were 
administered 
13
C6-leucine via drinking water to measure new protein synthesis after ASO 
treatment. Measures of new protein synthesis and protein concentration were assayed at 
designated time points after ASO treatment using targeted proteomics. ASO treatment lowered 
hTau mRNA and protein production (measured by 
13
C6-leucine-labeled hTau protein) earlier 
than total hTau protein concentration in transgenic mouse cortex. In the CSF of hSOD1 
transgenic rats, ASO treatment lowered newly generated hSOD1 protein driven by decreases in 
newly synthesized hSOD1 protein, not overall protein concentration 30 days after treatment. At 
later time points, decreases in newly generated protein driven by overall lowering of protein 
concentration, not the rate of newly synthesized protein. Taken together, measures of newly 
generated protein show earlier pharmacodynamics changes for RNA-lowering therapeutics 
compared with total protein concentration. However, a therapeutic window exists to measure 
new protein production before pharmacodynamics effects reach steady state. Measuring new 





The number of persons aged 65 and older globally is projected to triple by the year 2050 
(WHO 2012), increasing the number of people living with adult-onset, progressive 
neurodegenerative diseases in the population.  There is a dire need to develop novel therapeutics 
for these conditions, as current FDA-approved drugs do little more than manage symptoms, and 
no treatments exist to reverse disease pathology. Despite promise of new therapies in preclinical 
models over the past 30 years, these compounds have failed in Amyotrophic Lateral Sclerosis 
(ALS) and Alzheimer’s Disease (AD) clinical trials at rates greater than 95 and 99%, 
respectively (Cummings et al 2014; Petrov et al 2017).  One important way to improve the 
current treatment landscape is to focus on the development of novel methods to determine 
whether a therapeutic has engaged the intended target in human clinical trials.     
 A central hypothesis in neurodegenerative disease is that the accumulation of misfolded 
proteins over time imparts selective toxicity to specific neuronal populations, causing 
progressive neurodegeneration and manifestation of symptoms. This pathological misfolding of 
proteins in AD (Braak & Braak 1995), ALS (Neumann et al 2006; Shibata et al 1996), 
Parkinson’s Disease (PD) (Bethlem & Den Hartog Jager 1960), and Huntington’s Disease (HD) 
(DiFiglia et al 1997) suggests that an approach to inhibit the production of toxic proteins within 
the cell may be an effective therapy. One such approach includes lowering levels of RNA to 
decrease protein translation using molecules such as antisense oligonucleotides (ASOs) or small 
interfering RNA (siRNA). ASOs are short, DNA-like molecules that can be designed to 
selectively bind mRNA transcripts and cause the catalytic destruction of particular mRNAs 
(DeVos & Miller 2013a). ASOs that lower mRNA levels and thus decrease translation of 
proteins prone to misfolding show great promise in preclinical models of tauopathy (DeVos et al 
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2017), ALS (Becker et al 2017; Donnelly et al 2013; Smith et al 2006), and HD (McBride et al 
2011), and are relatively safe in humans (Miller et al 2013). These promising data have led to the 
launch of multiple clinical trials for ASOs in neurodegenerative diseases (NCT03225846, 
NCT02623699, NCT02519036, NCT03186989).  
 For RNA-targeted therapeutics, it is crucial to establish measurements that validate 
compound engagement with its desired biological target, mRNA (Mitsumoto et al 2014).  
However, it is challenging to isolate mRNA from cerebrospinal fluid (CSF), the primary biofluid 
available to assay target engagement in the human central nervous system (CNS). Because 
mRNA translation leads to the production of new protein, protein-based biomarkers in CSF 
represent an attractive avenue to pursue target engagement for RNA-targeted therapeutics. In this 
study, we used nonradioactive, stable isotope labeling with an essential amino acid (Bateman et 
al 2007; Bateman et al 2006)  to identify inhibition of new protein production after ASO 
treatment. Using two preclinical models of ASO targets in clinical trials for neurodegenerative 
disease, we tested the hypotheses that stable isotope labeling with 
13
C6-Leucine will: 1) identify 
pharmacodynamics at an earlier time point than protein concentration-based measures and 2) 
show measurable effects in CSF to support translation of this assay approach from animal 
models to human CNS. These results would support the use of new protein synthesis 




Transgenic Animals  
Transgenic mice expressing human tau (hTau) (Andorfer et al 2003) (Jackson 
Laboratories, Bar Harbor, ME) were maintained through in-house breeding on a C57/Bl6 
background. Transgenic rats expressing human superoxide dismutase-1 (hSOD1
WT
) (Chan et al 
1998) were provided by Pak Chan (Stanford University) and maintained through in-house 
breeding on a Sprague-Dawley background. Genotyping was performed by PCR amplification of 
tail DNA (Supplementary Table 1).  All breeding and experimental protocols were approved by 
the Institutional Animal Care and Use Committee at Washington University and conducted 
according to the NIH Guide for Care and Use of Laboratory Animals.  
Antisense Oligonucleotides (ASOs)  
ASOs that recruit RNase-H to degrade target mRNA and an inactive, control ASO with 
no sequence specificity were provided by Ionis Pharmaceuticals (DeVos et al 2017; McCampbell 
et al 2018) (Table 4.1). All ASOs were diluted in artificial CSF before use.  
Surgical Procedures 
All animals were anesthetized by 2-5% inhalant isoflurane, received constant isoflurane 
flow during the procedure, and were given an injection of bupivacaine prior to incision. 
Following the surgical procedure, animals received carprofen and were placed on a 37°C heating 
pad for recovery.  
For intracerebroventricular injections, 60-day-old hTau transgenic mice received 300 µg 





hTau ASO CCoGoToTTTCTTACCAoCoCT 
hSOD1 ASO TToAoATGTTTATCAoGoGAT 
Inactive ASO CCoToAoTAGGACTATCCAoGoGoAA 
Table 4.1. Antisense Oligonucleotides 
Oligonucleotides containing phosphothioate backbone modifications: unmodified phosphodiester 
linkage (red o),  2’-O-methoxyethylribose, (orange) and constrained ethyl (blue) groups.  All 
cytosine residues are 5’methylcytosine. 
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Similarly, 120-day-old hSOD1 transgenic rats received 1000 µg of ASO injected at -1.4mm 
M/L, -0.4mm A/P, -3.5mm D/V from Bregma. For intrathecal ASO injection, 120-day-old 
hSOD1 transgenic rats received 1000 µg of ASO between the L3 and L5 vertebrae (Mazur et al 
2017). Both male and female transgenic animals were used in these studies, and researchers were 
blinded to the identity of treatment throughout the duration of the experiment.  
13
C6-Leucine Oral Labeling and Tissue Collection 
 Methods for oral labeling in rodents with 
13
C6-Leucine were described previously using 
unlabeled L-leucine or labeled, 
13
C6-L-Leucine (Cambridge Isotope Laboratories, Cambridge, 
MA) dissolved in water at 5 mg/mL  (Crisp et al 2015). Labeling was consistent in all 
experiments between groups (Supplementary Figure 1). 
 At indicated time points after surgery, animals were anesthetized with isoflurane and 
perfused with cold phosphate buffered saline (PBS) containing 0.03% heparin. Before perfusion, 
CSF was extracted from rat cisterna magna via a 23x¾” winged infusion butterfly needle 
(Terumo, Somerset, NJ). Blood was collected from mechanically ruptured vena cavae at 
beginning of perfusion, and the brain and spinal cord were harvested after perfusion. All samples 
were flash frozen in liquid nitrogen and stored at -80 °C before use.  
mRNA Isolation and Analysis  
 mRNA isolation from flash-frozen tissues was performed using the RNeasy® Mini Kit 
(Qiagen, Venlo, Netherlands). The EXPRESS One-Step Superscript qRT-PCR Universal Kit 
(Invitrogen, Carlsbad, CA) was used for reverse transcription and amplification of SOD1 and 
MAPT mRNA transcripts. Comparative analysis by the ΔΔCt method, with GAPDH mRNA 
transcripts as an internal control, was performed with the ABI PRISM 7500 Fast Real-Time 
System (Applied Biosystems, Waltham, MA) (Supplementary Table 1).  
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N15 Recombinant Protein Standards  
 N15-labeled, recombinant hTau protein (isoform 2N4R 411) was a generous gift from 
Drs. Isabelle Huvent and Guy Lippens (Université des Sciences et Technologie de Lille 1, 
France).  
 Recombinant hSOD1 was produced in Rosetta 2 E Coli (Novagen) using an hSOD1 
cDNA construct with an N-terminal GST tag subcloned into a pGEX4T-1 backbone. Bacterial 
cultures were inoculated overnight in 15N-Celtone Complete Medium (Cambridge Isotope 
Laboratories, Inc) with shaking at 37°C and induced with 1mM IPTG for hSOD1 production. 
Protein was isolated by incubation with 600 µL of glutathione sepharose 4B beads (GE 
Healthcare) for 30 minutes, 1 unit of thrombin (Thrombin Cleavage Capture Kit, Millipore) for 
20 hours, and 30 µL of streptavidin agarose for 30 minutes, performed at room temperature. 
Samples were spun at 1,000xg for 5 minutes, and supernatant containing N15-labeled, hSOD1 
recombinant protein was collected. 
Tissue Homogenization, Protein Isolation, and Mass Spectrometric Analysis  
 hTau transgenic mouse brain tissue was homogenized in PBS plus protease inhibitors 
(P8340; Sigma-Aldrich, St. Louis, MO). Protein concentration of brain lysate was determined by 
Pierce BCA assay (ThermoFisher Scientific, Waltham, MA). Total hTau was 
immunoprecipitated from 100 µg of tissue lysate using 30 µL of CNBr-activated Sepharose 
beads (GE Healthcare, Chicago, IL) crosslinked to anti-hTau antibody (Tau 1 monoclonal, 
produced by Nicholas M. Kanaan, Michigan State University) at 3 mg antibody/g of beads in 1 
mL PBS plus 1% NP-40, 5 mM guanidine, and protease inhibitors for 1.5 hours at room 
temperature. Before immunoprecipitation, 5 ng of N15-lableled hTau was added to each sample. 
hTau was digested using 400 ng of sequencing-grade endoproteinase Trypsin (Promega, 
86 
 
Madison, WI) for 16 hours at 37°C. Samples were lyophilized and reconstituted in 25 uL of 2% 
acetonitrile/0.1% formic acid solution prior to liquid chromatography- quadrupole-orbitrap mass 
spectrometry analysis (OrbiTrap Fusion, ThermoFisher).   
hSOD1 was isolated from transgenic rat tissue or CSF as described previously (Crisp et al 
2015). Before immunoprecipitation, 200 ng of N15-labeled hSOD1 was added to each brain or 
spinal cord sample, and 50 ng of N15 SOD1 was added to CSF samples. Isolated hSOD1 was 
digested with 600 ng of sequencing-grade endoproteinase GluC in 25 µL of 50 mM NaHCO3 
buffer (pH 8.8) for 17 hours at room temperature. After solid phase extraction, samples were 
lyophilized and resuspended in 25 µL 2% acetonitrile/0.1% formic acid solution prior to liquid 
chromatography-triple quadrupole mass spectrometry analysis (Xevo TQ-S, Waters).   
Newly synthesized proteins were quantified by analyzing the incorporation of 
13
C6-
Leucine into target proteins, indicated by the tracer-to-tracee ratio (TTR), by comparing the area 





Leucine. Relative protein concentration was quantified by measuring the ratio between the area 
under the curve of protein immunoprecipitated from animal tissue and N15-labeled recombinant 
protein (Supplementary Tables 4.2 and 4.3). To account for non-steady state conditions due to 
mRNA lowering in this experiments, newly generated protein was also analyzed by multiplying 
the relative protein concentration by protein TTR at each time point. For figure presentation, data 
for hTau is represented by the TPSLPTPPTR peptide and data for hSOD1 is represented by the 
GLHGFHVHE peptide.  
Plasma-free 
13
C6-Leucine abundance was analyzed from TCA precipitation of 100 µL rat 
or mouse plasma via capillary gas chromatography-negative chemical ionization-quadrupole 
mass spectrometry (Agilent) as described previously (Crisp et al 2015).  
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Statistical Analysis  
 All statistical analyses were performed using Graphpad Prism 7.0 (GraphPad Software). 
All hypothesis tests performed were two-sided assuming a normal distribution of data. P < 0.05 
was determined significant. Based on previous results (DeVos et al 2017; McCampbell et al 
2018), a cutoff of 50% target mRNA reduction relative to the mean mRNA levels in inactive 
ASO-treated animals was used as inclusion criteria for subsequent analysis. In CSF analysis, 
samples were excluded if blood contamination was visibly present or if the volume of CSF 
collected was less than 75 uL. For relative quantification, samples were normalized to a single 
sample in each experiment from the inactive ASO treatment group. Quantitative results are 




Lowering New hTau Production Precedes Protein Concentration Changes after ASO Treatment  
We performed ICV injection of an ASO targeting human tau mRNA (DeVos et al 2017) 
in transgenic mice expressing the human tau transgene (hTau mice) to understand lowering of 
tau mRNA and total protein over time. To analyze newly generated hTau protein, we 
administered 
13
C6-Leucine in the drinking water at designated time points (Figure 4.1A). We 
organized the timing of ASO treatment, 
13
C6-Leucine administration, and euthanasia to observe 
consistent, maximum label incorporation of proteins within the CNS at each time point assayed . 
hTau ASO treatment lowered hTau mRNA in the cerebral cortex over time (Figure 
4.1B). As early as two days post-injection, hTau ASO treatment lowered hTau mRNA levels by 
~50% relative to inactive ASO, with further change of hTau mRNA by ~72% by 23 days post-
injection. hTau ASO treatment also decreased hTau protein levels over time (Figure 4.1C), with 
significant effects of ~32% observed at 23 days. The discrepancy between overall mRNA 
lowering and protein lowering is consistent with tau as a long-lived protein in the CNS (Sato et 
al 2018). 
Using percent of 
13
C6-Leucine incorporation (TTR) as a measure of newly synthesized 
protein, hTau ASO treatment lowered of newly synthesized hTau protein over time (Figure 
4.1D). We observed lowering of new hTau protein production at 13 days after ASO treatment by 
~71%. Combined, these data suggest that newly generated hTau protein is a reliable measure of 
hTau ASO pharmacodynamics in central nervous system tissue, with newly generated hTau 
showing an earlier (13 vs. 23 days) and greater magnitude of effect (71% vs. 32%) compared to 























(A.) Experimental Design. hTau transgenic mice received 300 μg of either hTau ASO or inactive 





designated time points. (B.) hTau mRNA levels in temporal cortex by qPCR. Compared to 
inactive ASO control, hTau ASO treatment lowered hTau mRNA over time (2-Way ANOVA F3,24 
= 10.04, p = 0.0145).  hTau mRNA levels are significantly lowered as early as two days after 
ASO treatment by 50% (95% CI: 34.8%, 66.9%), and remain lowered as late as 23 days post 
treatment by 72% (55.5%, 87.2%). (C.) hTau protein levels relative to N15-labeled recombinant 
standard in temporal cortex by LC-MS. hTau ASO treatment lowers hSOD1 protein over time 
 
Figure 4.1 Lowered hTau protein synthesis precedes protein lowering after ASO 
treatment in hTau transgenic mice 
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(2-Way ANOVA F3,24 = 3.374, p = 0.0349). This effect is observed at 23 days post ASO treatment 
by 32% (0.05%, 64.0%). (D.) Newly synthesized 
13
C6-Leu-labeled hTau in temporal cortex by 





unlabeled hTau. Lowering of 
13
C6-Leu-labeled hTau is observed over time (2-Way ANOVA, 
F3,24 = 5.748, p = 0.0041), and as early as 13 days post ASO treatment by 71% (95% CI: 29.4%, 
123%). (E.) Newly generated hTau protein measured by multiplying hTau protein concentration 
and TTR to account for non-steady state conditions. **** p < 0.0001, *** p < 0.001, ** p < 0.01. 







C6-Leucine-labeled hSOD1 Occurs in CSF after ASO Treatment  
 hSOD1
WT
 rats were treated with an ICV injection of 1000 µg hSOD1 ASO in the lateral 
ventricle and administered 
13
C6-Leucine in drinking water (Figure 4.2A). Based upon previous 
measurements of hSOD1 half-life in these rats (Crisp et al 2013), and that lowering of CSF 
SOD1 after ASO treatment in the G93A SOD1 transgenic rat model was observed at 42 days 
post ASO treatment (Winer et al 2013),  we euthanized animals 30 days after treatment to assay 
hSOD1 total protein levels and new hSOD1 protein production to look for early ASO 
pharmacodynamics. hSOD1 ASO treatment lowered hSOD1 mRNA globally within the CNS 
(Figure 4.2B), leading to overall hSOD1 protein lowering by ~62%  in cortex and ~40%  in 
lumbar spinal cord (Figure 4.2C). Similarly, we observed a decrease in newly synthesized 
hSOD1 protein by ~34% in cortex and ~50% in lumbar spinal cord (Figure 4.2D). At this time 
point, lowering of both hSOD1 protein concentration and newly synthesized hSOD1 protein 
drive overall decreases in newly generated hSOD1 protein (Figure 4.2E). 
In CSF, hSOD1 treatment failed to lower hSOD1 protein concentration (Figure 4.2F).  
However, SOD1 ASO treatment decreased newly synthesized 
13
C6-Leucine-labeled hSOD1 in 
CSF by ~30% relative to the inactive ASO treatment group (Figure 2G). This effect of lowered 
13
C6-Leucine-labeled hSOD1 is specific to CSF, as we did not measure any differences in 
peripheral hSOD1 protein in plasma (Supplemental Figure 4.1). To test SOD1 protein 
concentration at a later time point, we treated a separate cohort of animals without 
13
C6-Leucine 
labeling using the same ASO treatment paradigm and analyzed CSF hSOD1 concentration at 50 
days post-surgery (Supplemental Figure 4.5). Although we observed lowering in hSOD1 
mRNA throughout the CNS 50 days post-ASO treatment (Supplemental Figure 4.5A), we did 
not observe decreases in CSF hSOD1 protein concentration (Supplemental Figure 4.5B), 
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suggesting an even longer incubation time may be required to observe protein lowering in CSF.  
Taken together, these data suggest changes in newly synthesized, 
13
C6-Leucine-labeled target 
proteins drives early pharmacodynamics biomarker effects in the CSF after ASO treatment 







Figure 4.2 Lowered 
13
C6-Leucine-labeled hSOD1 observed in cerebrospinal fluid after ASO 




(A.) Experimental Design. hSOD1 transgenic rats received 1000 μg of either hSOD1 ASO or 
inactive ASO via intracerebroventricular injection at designated time points. (B.) hSOD1 mRNA 
levels in the CNS by qPCR. hSOD1 mRNA levels are lowered globally in the CNS, with mRNA 
lowering of ~70% in cortex and lumbar spinal cord and ~55% in cerebellum. (C.) hSOD1 protein 
levels relative to N15-labeled recombinant standard in CNS cortex by LC-MS. Lowering of 
hSOD1 protein is observed in both cortex at ~61% (95% CI: 41.9%, 81.3%) and lumbar spinal 




C6-Leu) labeled hSOD1 in CNS by LC-MS. 





hSOD1. Significant lowering of 
13
C6-Leu-labeled hSOD1 is observed in both cortex at ~34% 
(15.5%, 51.9%) and lumbar spinal cord at ~50% (33.3%, 66.1%). (E.) Newly generated hSOD1 
protein measured by multiplying hSOD1 protein concentration and TTR in tissues. (F.) hSOD1 
protein levels relative to N15-labeled recombinant standard in CSF by LC-MS. No changes in 
CSF hSOD1 protein levels were observed (Student’s T-Test  t = 0.448, p = 0.67). (G.) 
13
C6-Leu 
labeled hSOD1 in CSF by LC-MS. Significant lowering of 
13
C6-Leu-labeled hSOD1 by ~30% 
(95% CI: 12.0%, 48.4%) observed relative to inactive ASO control (Student’s T Test  t = 3.923, p 
= 0.0057). (H.) Newly generated hSOD1 protein measured by multiplying hSOD1 protein 
concentration and TTR in CSF. One sample in inactive ASO group was excluded in CSF 
analysis due to blood contamination during CSF collection. **** p < 0.0001, *** p < 0.001, ** p 




A Therapeutic Window Exists for Newly Synthesized Protein Pharmacodynamics 
 To enhance the translational relevance of our findings, we performed similar experiments 
in hSOD1 rats using intrathecal ASO injection, the method of drug delivery used in current 
clinical trials. We analyzed CNS tissue 10, 30, and 60 days after ASO treatment compared to 
inactive ASO control to better understand longitudinal changes in hSOD1 protein (Figure 4.3A). 
Contrary to hSOD1 ASO delivery by ICV injection, we observed differential effects of hSOD1 
mRNA lowering in CNS tissues after intrathecal ASO injection. We observed a significant 
hSOD1 mRNA decrease in the lumbar spinal cord over time, with an average hSOD1 mRNA 
lowering at 60 days by ~66%.  However, hSOD1 treatment did not significantly lower hSOD1 
mRNA in the cortex or cerebellum over time (Figure 4.3B).  Because it is likely that SOD1 
mRNA will need to be lowered globally in the CNS to affect SOD1 CSF levels, we focused on 
protein measurements in the spinal cord, where we confidently documented mRNA lowering.    
 To further understand the relationship between protein lowering and lowering of newly 
synthesized hSOD1 after ASO treatment, we analyzed hSOD1 protein in lumbar spinal cord. 
hSOD1 ASO treatment decreased hSOD1 protein levels across all time points measured, and 
treatment effect was greatest at day 60, with 50% lowering of hSOD1 protein (Figure 4.3C).  
hSOD1 ASO treatment significantly lowered newly synthesized hSOD1 compared to inactive 
ASO-treated animals (Figure 4.3D). Interestingly, ASO treatment decreased newly synthesized 
hSOD1 at 10 and 30 days by 40 and 45%, but there was no difference in 
13
C6-Leucine-labeled 
hSOD1 between groups at day 60 due to lowering of total hSOD1 protein concentration. 
Therefore, at later time points, decreases in newly generated hSOD1 protein by ASO treatment 




Figure 4.3 A therapeutic window exists to observe lowered protein synthesis 
pharmacodynamics in the central nervous system 
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(A.) Experimental Design. hSOD1 transgenic rats received 1000 ug of either hSOD1 ASO or 
inactive ASO at designated time points via intrathecal injection. (B.) hSOD1 mRNA levels in the 
CNS by qPCR. hSOD1 mRNA levels are significantly lowered in spinal cord after hSOD1 ASO 
treatment (2 Way ANOVA  F2,39 = 10.91, p = 0.002), with a maximum lowering of ~66% (95% 
CI: 54.6%, 78.2%)  60 days post-treatment. No significant hSOD1 mRNA lowering was 
observed in frontal cortex (2 Way ANOVA F2,40 = 1.48, p = 0.24) or cerebellum. (C.) hSOD1 
protein levels relative to N15-labeled recombinant standard in lumbar spinal cord by LC-MS. 
Lowering of hSOD1 protein is observed at over time (2 Way ANOVA F2,36 = 10.04, p = 0.0004), 
with a maximum lowering by ~50% (95% CI: 42.5%, 79.8%) at Day 60. (D.) 
13
C6-Leu labeled 





C6-Leu-unlabeled hSOD1. Significant lowering of newly synthesized hSOD1 observed 
after hSOD1 ASO Treatment (2 Way ANOVA F2,36 = 6.269, p = 0.0046).  Lowering of 
13
C6-
Leu-labeled hSOD1 is observed 10 and 30 days after ASO treatment by ~40-45% (30%, 88%). 
60 days post ASO treatment, there was no difference in 
13
C6-Leu-labeled hSOD1 between groups 
(adjusted p value = 0.9976). (E.) Newly generated hSOD1 protein measured by multiplying 
hSOD1 protein concentration and TTR in tissues. **** p < 0.0001, *** p < 0.001, * p < 0.05. 
hSOD1 ASO: n = 5 - 10 per time point, Inactive ASO: n = 5 – 7 per time point. Error bars in 





Our data show that, following treatment with a mRNA lowering therapeutic, the lowering 
of newly synthesized protein occurs before lowering of total protein concentration in tissue.  
Further, our findings indicate that labeled, newly generated protein measures direct effects of 
protein translation in the source tissues, which are not seen in CSF protein concentrations at early 
time points.  Given the direct measurement of protein translation, labeling protein production has 
higher sensitivity than protein concentration-based measures for mRNA-lowering therapies. 
These studies suggest that identifying newly generated protein after ASO treatment is an 
effective protein-based biomarker for assaying ASO target engagement (Figure 4.4). 
Previous work supports the use of CSF protein concentration as a promising 
pharmacodynamics biomarker for ASO therapy (Gendron et al 2017; Winer et al 2013), and CSF 
SOD1 concentration is a secondary outcome measurement in an ongoing Phase I clinical trial 
(NCT0262399). However, a key limitation in the use of CSF protein concentration as a measure 
of ASO efficacy is the indirect mechanism informed by this assay. ASOs inhibit the production 
of new protein, and measures of protein concentration also rely on transport to CSF and the 
clearance of existing protein which may be unaffected by ASO treatment. Especially in a rapidly 
progressing neurodegenerative disease such as ALS (Bali et al 2017), it is important to develop 
pharmacodynamics tools that identify direct mechanisms of action at early time points that 
reflect the actual drug effect in the tissue of interest.  
Our study design is translatable to humans, as stable isotope labeling is safe and effective 
in measuring the kinetics of proteins implicated in neurodegenerative disease within human CSF 





















(A.) Normal protein turnover at steady state synthesis includes production (top arrow) and 
clearance (bottom arrow) rates in the CNS. (B.) Early after treatment, lowering in new protein 
synthesis is observed due to lowering of target mRNA. (C.) In addition to lowering of new 
protein synthesis, proteins present before 
13
C6-labeling are cleared at the rate of turnover or half-
life. (D.) mRNA lowering reaches steady state, resulting in a consistent lowered protein synthesis 
rate. Protein clearance remains constant and faster than production, leading to a new lowered 
steady state protein concentration detected at a later time and less magnitude.     
 
Figure 4.4 A model of the interplay between new protein production and protein 
concentration pharmacodynamics in RNA-lowering treatment strategies 
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However, these experiments were performed over a 36-hour time period, as the half-life of 
amyloid beta peptide is ~9 hours in CSF (Bateman et al 2006). To our knowledge, the results 
presented here are the first observations measuring new protein production of long-lived protein 
targets in the CNS after therapeutic intervention. Our approach can be directly applied to 
multiple RNA-directed strategies, such as siRNAs (Pfister et al 2009) and ASOs (Huynh et al 
2017; Zhao et al 2017a), that target long-lived proteins in neurodegeneration for clinical trials. 
Besides its lowered protein production readout, stable isotope labeling could be a powerful tool 
to examine increased protein production for therapeutic strategies such as gene therapy 
(Tuszynski et al 2015) and splicing ASO treatments (Finkel et al 2017; Schoch et al 2016).  
Moreover, an understanding of protein kinetics using stable isotope labeling can also inform on 
assays for therapies that target protein turnover, such as those approaches that activate protein 
clearance mechanisms (Lee et al 2010) or promote proper protein folding (Das et al 2015).  
Another advantage of our mass spectrometry-based assay is the ability to specifically 
isolate mutant from wild type protein in patient populations. Many familial forms of 
neurodegenerative diseases are caused by autosomal dominant mutations [31] and, thus, exhibit 
both mutant and normal protein forms. However, it is currently unknown if mutant proteins 
display altered protein kinetics compared to their wild type counterparts in humans. Future 
studies in symptomatic, mutation-carrying patients are needed to characterize the half-life of 
these target proteins in human CSF.  Protein half-life measures will be crucial to determine the 
timing required to observe pharmacodynamics effects in humans when designing randomized-
control clinical trials. 
One limitation in this study is the inability to identify target protein lowering in CSF after 
SOD1 ASO treatment. Without this effect, the relationship between lowered protein production 
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and total protein concentration cannot be determined in the biological fluid important for human 
clinical trials. Previous data suggests this limitation may be due to the drug delivery paradigm in 
these experiments. The current study used a single bolus injection of ASO in rodent models 
while previous studies that observed total target protein lowering in CSF after ASO treatment in 
non-human primate models were performed with multiple intrathecal ASO injections (DeVos et 
al 2017; McCampbell et al 2018).  Additionally, both transgenic animal models used here 
express wild type forms of the target protein, where no pathological misfolding of either hSOD1 
or hTau is observed (Andorfer et al 2003; Chan et al 1998). Therefore, future studies should 
examine how new protein production changes in the presence of misfolded proteins within the 
CNS.    
In sum, the approach described here provides a framework for the development of assays 
that isolate the direct mechanism of action of target engagement in neurodegenerative disease 
therapies, with the hope that such data will lead to a higher success in clinical trial outcomes and 
approval of more therapies for patients.   
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MAPT Genotyping Reverse  5’-CTGTGCATGGCTGTCCACTAACCTT -3’ 
 
SOD1 Genotyping Forward  5’-TTGTTCAGAAAACTCTCTCCAACTTTGCACT-3’ 
 
SOD1 Genotyping Reverse  5’- GGGTTTTAACGTTTAGGGGCTACTCTACTG -3’ 
 
MAPT qPCR Forward 5’-AGAAGCAGGCATTGGAGAC-3’ 
 
MAPT qPCR Reverse 5’-TCTTCGTTTTACCATCAGCC-3’ 
 
MAPT qPCR Probe 5’-/56-FAM/ACGGGACTGGAAGCGATGACAAAA/3IABkFQ/-3’ 
 
SOD1 qPCR Forward  5’-TGCATCATTGGCCGCA-3’ 
 
SOD1 qPCR Reverse  5’-TTTCTTCATTTCCACCTTTGCC-3’ 
 
SOD1 qPCR Probe 5'- /56FAM/ACTGGTGGTCCATGAAAAAGCAGATGACTT/36-
TAMTph/-3' 
 
GAPDH qPCR Forward 5’-TGCCCCCATGTTGTGATG -3’ 
 
GAPDH qPCR Reverse  5’-TGTGGTCATGAGCCC TTCC -3’ 
 
GAPDH qPCR Probe 5’- /56-FAM/AATGCATCCTGCACCACCAACTGCTT/3IABkFQ/-3’ 
 
Supplementary Table 4.1 Primers and probes used for genotyping and qPCR analysis of 








 557.9737 547.3086 19 
 
 
 557.9737 707.4087 14 
   557.9737 735.9194 14 
   557.9737 804.4462 14 
  
13
C6-Leu 559.9804 553.3287 19 
   559.9804 710.4187 14 
   559.9804 738.9294 14 
   559.9804 810.4663 14 
  N15 564.6206 553.2908 19 
   564.6206 715.3849 14 
  564.6206 744.3942 14 




  516.754 308.1717 13 
  516.754 649.32 18 
   516.754 725.336 18 
   516.754 748.388 18 
  
13
C6-Leu 519.764 314.1918 13 
   519.764 655.3406 18 
   519.764 725.3365 18 
  519.764 754.4090 18 
 N15 524.2319 313.1569 13 
  524.2319 659.2909 18 
  524.2319 735.3069 18 
 




   756.3083 425.2199 26 
   756.3083 474.7541 26 
   756.3083 565.2841 31 
   756.3083 910.9479 21 
  
13
C6-Leu 758.3870 428.2300 26 
   758.3870 477.7642 26 
   758.3870 565.2841 31 
   758.3870 913.9850 21 
  N15 766.0183 432.1992 26 
  766.0183 482.2319 26 
 
 766.0183 575.2545 31 
 
 766.0183 923.4109 21 
 
Supplementary Table 4.2 Transition ions used for hSOD1 tandem LC-MS/MS. 








 533.7982 668.3726 20 
 
 13
C6-Leu 536.8083 668.3726 20 




  655.3629 658.3729 15 
  
13




  431.2374 691.3621 15 
  
13
C6-Leu 434.2475 697.3822 15 
 
Supplementary Table 4.3 Transition ions used for hTau tandem LC-MS/MS. TPSLPTPPTR 























C6-Leucine values were analyzed in all samples analyzed and compared between 
groups. (A.) hTau ICV ASO plasma 
13
C6-Leucine at Day 23 post surgery, as seen in Figure 1. No 
differences were observed (Student’s T-test, p =0.4496). (B.) hSOD1 ICV ASO plasma 
13
C6-
Leucine at Day 30. No differences were observed (Student’s-T test) (C.) hSOD1 IT ASO plasma 
13
C6-Leucine at all time points assessed. No differences were observed (2-Way ANOVA). Error 
bars in figures represent SEM. 
 
Supplementary Figure 4.1 No differences in 
13
C6-Leucine oral labeling between 










Linear regression analysis comparing peptides shows strong correlations exist between all three 
peptide measurements. All p values < 0.0001 for each analysis. 
 




















Linear regression analysis comparing peptides shows strong correlations exist between all three 
peptide measurements. All p values <0.0001 for each analysis.  
 












(A.) hSOD1 protein levels relative to N15-labeled recombinant standard by LC-MS in plasma. 
No changes in plasma hSOD1 protein levels were observed (Student’s T-test). (B.) 
13
C6-Leu 
labeled hSOD1 in plasma by LC-MS. No changes in plasma 
13
C6-Leu labeled hSOD1 was 
observed (Student’s T-Test). Error bars in figures represent SEM. 
 
Supplementary Figure 4.4 No pharmacodynamics observed in the periphery after 1000 ug 




Supplementary Figure 5 No protein concentration pharmacodynamics observed in CSF 
after 1000 ug hSOD1 ASO intracerebroventricular injection at 50 days post-treatment. 
(A.) hSOD1 mRNA levels in the CNS by qPCR. hSOD1 mRNA levels are significantly lowered 
in spinal cord and frontal cortex by ~70% and 50%, respectively, after ASO treatment relative to 
inactive ASO controls (Student’s T-test).  (B.) hSOD1 protein levels relative to N15-labeled 
recombinant standard by LC-MS. No changes in CSF hSOD1 protein levels were observed 
(Student’s T-test). n = 5 for each treatment group, with one CSF sample excluded from each 











Chapter 5: Summary and Future Directions 
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Advances in elucidating the genetic causes of ALS and generating models of disease 
have rapidly enhanced our understanding of ALS pathophysiology in recent years, leading to the 
development of multiple drug candidates for this devastating condition. However, multiple 
challenges still exist for successful translation of preclinical discoveries to effective therapies in 
the clinic. In this dissertation, I presented novel findings that further the understanding of human 
ALS epidemiology and CSF SOD1 biology. Further, these findings generate crucial parameters 
that can be directly implemented into randomized control clinical trial design for ALS patients.  
ALS
SOD1
 clinical outcomes remain unchanged over time      
 In Chapter 2, I detailed findings from a retrospective cohort study to examine ALS
SOD1
 
across 15 medical centers in the United States and Canada. Multiple studies in the late 1990’s 
and early 2000’s characterized the natural history of the ALS
SOD1
 population, but our efforts to 
analyze 175 subjects represent the largest patient population in almost 20 years. With the advent 
of multidisciplinary care for the ALS patient population, previous studies reported an 
improvement in ALS natural history, as defined by slower disease progression, from the end of 
the 19
th
 century to the beginning of the 20
th
 century (Czaplinski et al 2006b; Qureshi et al 2009). 
Therefore, it is important to determine if similar trends exist specifically in the ALS
SOD1
 
population, as such trends will improve our understanding of clinical outcomes and influence 
randomized control trial design for new potential treatments in this disease population.  
       Our calculated mean disease duration for all ALS
SOD1
 is similar to previous studies 
(Table 2.1). Of particular interest in ALS
SOD1
 epidemiology is the A4V point mutation that 
accounts for ~50% of the disease population in North America. Indeed, the highest percentage of 
patients in our analysis carried the A4V mutation, and our calculated mean disease duration of 
1.4 ± 0.7 years is unchanged compared to previous studies (Table 2.2). These data have 
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important implications, as the contrast to the trend of slower disease progression in the entire 
ALS population over time suggests ALS
SOD1
 may be a unique subpopulation of disease. 
As multiple therapeutic candidates are emerging to target SOD1 in ALS (Benatar et al 
2018; Miller et al 2013), our natural history data have important implications for randomized 
control trial design. Previous ALS trial enrollment is low and highly variable between study 
sites, presenting a need to design more efficient clinical trials (Bedlack et al 2008). From our 
natural history data, multiple opportunities exist for such considerations in the ALS
SOD1
 
population. The increased prevalence of A4V mutations in the SOD1 population suggests 
stratification of trial data to this specific mutation population. Such a strategy may be feasible 
due to the limited variability in survival of SOD1
A4V
 patients, as our survival analysis showed no 
SOD1
A4V
 patients living past 3.5 years (Figure 2.2). Indeed, our power calculations showed that 
only 52 SOD1
A4V
 subjects per treatment group are needed to show hazard ratio of 0.5 the 
experimental and control treatment groups. In contrast, 88 subjects per treatment group from the 
entire SOD1 population are needed to detect the same statistical difference in median survival. 
Moreover, unchanged natural history of ALS
SOD1
 may provide support for the use of 
historical controls in early phase (I/II) trials (Donofrio & Bedlack), as seen in previous studies 
(Miller et al 2011). The use of historical controls addresses many of the challenges associated 
with previous clinical trial design, including reduced cost, improved efficacy, and appeal to 
patients (Gordon 2009). Czaplinski and colleagues argued that historical controls are particularly 
useful for experimental compounds that have received FDA approval for other indications, as 
data for safety in humans already exists (Czaplinski et al 2006a). However, multiple limitations 
exist in the use of historical controls such as matching bias, and the lack of key clinical 
information such as comorbidities, current medication use, site of disease onset, and others. 
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Therefore, in future ALS natural history studies, it is important to collect data in a prospective 
manner, capturing all clinically relevant data in the ALS
SOD1
 population. These data will be 
crucial for not only improving clinical trial design in ALS, but further understanding the factors 
that contribute to ALS pathobiology to better understand patient prognosis.    
Understanding drivers of ALS
SOD1 
heterogeneity  
 My results also show that the remaining, non-A4V ALS
SOD1
 population exhibits highly 
variable measures in mean age of disease onset (49.5 ± 12.3 years) and mean disease duration 
(6.6 ± 7.0 years) (Table 2.1). We identified 36 missense variants in our cohort (Figure 2.1), and 
150+ variants have been identified as pathogenic in ALS, yet these variants exhibit a varying 
degree of disease penetrance (Felbecker et al 2010; Lopate et al 2010). Taken together, these 
observations question the validity of all SOD1 variants as pathogenic. Further efforts must be 
made in understanding this variability in the global ALS
SOD1
 population, as the majority of data 
have focused on the North American disease population. Interestingly, Rechtman and colleagues 
reported gender and ethnic differences in ALS incidence and age at diagnosis in the United 
States (Rechtman et al 2015).  Particular  geographic areas of interest to update ALS
SOD1
 natural 
history include Europe (Gamez et al 2006), Canada (Eisen et al 2008), and Asia (Chen et al 
2015). Therefore, a combination of natural history data and more rigorous genome sequencing 
data with advanced techniques (MacArthur et al 2014) may provide valuable insight into 
understanding the pathogenicity of each SOD1 variant as a contributor to disease.  
 A missing component in many natural history studies, including our data, is an analysis 
considering comorbidities and environmental factors as contributors to disease outcomes. 
Environmental and lifestyle factors such as chemical toxins (Su et al 2016), smoking (Alonso et 
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al 2010; Armon 2009), military service (Weisskopf et al 2015; Weisskopf et al 2005), and 
physical activity (Beghi et al 2010; Pupillo et al 2014) have all been implicated as risk factors of 
ALS. These environmental factors may contribute to the heterogeneity of outcomes observed 
between and within different SOD1 ALS variants, highlighting one of the key limitations in 
retrospective cohort analyses. A further understanding of the interplay between genetics and 
environmental contributions to ALS disease pathogenesis will be invaluable for the application 
of prognostic models to individual patient management (Westeneng et al 2018). Further, 
understanding of environmental factor contribution may help in formulating inclusion criteria for 
randomized control trials, limiting the variability in primary and secondary outcome measures to 
improve the statistical power of Phase II/III efficacy studies.  
CSF SOD1 is a long-lived protein in ALS  
 In Chapter 3, I showed the first efforts to determine CSF SOD1 protein concentration and 
kinetics in ALS patients using stable isotope labeling of essential amino acids combined with 
tandem liquid chromatography-mass spectrometry. In these participants, 
13
C6-Leucine-labeled 
SOD1 persists as long as 120 days after the end of the 16 hour  labeling period, further validating 
previous observations (Crisp et al 2015) that SOD1 is a long-lived protein within the CNS of 
humans (Figure 3.1). Additionally, CSF SOD1 protein concentration appeared to be increased in 
ALS participants compared to controls (Table 3.2), similar to previous results measured by CSF 
SOD1 ELISA (Winer et al 2013).  Variability and limited sample size inhibited conclusive 
differences in CSF SOD1 half-life between groups, with a calculated average of ~20 – 25 days 
(Table 3.2). CSF SOD1 half-life is a crucial parameter for randomized control trial design for 
experimental therapies in ALS
SOD1
, as CSF SOD1 protein concentration is a secondary outcome 
measure in current trials that inhibit the synthesis of new SOD1 protein (NCT01083667, 
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NCT02623699). Effects observed by these experimental treatments are influenced by the 
intrinsic synthesis and degradation rates of SOD1 in the CNS at steady state, as defined by the 
protein’s half-life. This relationship is clearly illustrated through PK-PD modeling, as we 
demonstrated how a calculated CSF SOD1 half-life of 25 days will result in an incubation time 
of ~120 days to observe changes in CSF SOD1 protein concentration after SOD1 ASO treatment 
(Figure 3.2). These kinetic parameters are also valuable for improving participant experience in 
clinical trials, as an understanding of the PK-PD relationship of experimental treatments may 
reduce the number of invasive procedures such as lumbar punctures that must be performed in 
order to establish therapeutic efficacy of drug target engagement.        
Analyzing CSF SOD1 protein behavior to elucidate contributions to ALS pathobiology 
 Besides considerations for clinical trial design, an understanding of SOD1 kinetics may 
provide valuable insight into the pathogenic status of SOD1 in ALS. Previous efforts to identify 
misfolded SOD1 in biofluids of living ALS patients, even those with SOD1 mutations, have 
remained elusive. Additionally, the role of misfolded SOD1 in sporadic ALS remains 
controversial. Similar to observations of alterations in protein turnover in human 
neurodegenerative disease, determination of CSF SOD1 protein turnover may provide an 
opportunity to interrogate the stability of SOD1 protein within the CNS of ALS patients. 
Moreover, if the degree of misfolded, aggregated protein in the brain and spinal cord of ALS 
patients relates to protein stability, an attractive hypothesis is that potential changes in SOD1 
protein kinetics may better inform on the prognosis of ALS patients. Currently, we are 
underpowered to test this hypothesis, as to-date, we only have three participants (each harboring 
different SOD1 mutations). However, my analysis in these SOD1 mutant carriers is the first to 
dissociate wild type from mutant protein kinetics in the cerebrospinal fluid of patients with 
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mutations that cause an autosomal dominant form of a neurodegenerative disease. With the 
recruitment of more participants, we hope to further investigate questions related to the 
potentially misfolded state of mutant SOD1 protein including: the ability to identify misfolded 
SOD1 in CSF, the role of SOD1 dimerization affecting protein stability in vivo, and how SOD1 
stability may differentiate between pathogenic and benign variants as contributors to ALS 
pathobiology. 
 Accumulating evidence in vitro and in vivo suggests that we may see altered CSF SOD1 
protein kinetics in ALS, indicative of SOD1 protein misfolding in the CNS. In cell culture, the 
half-life of soluble, mutant SOD1 is accelerated compared to WT protein (Borchelt et al 1994). 
Similar behavior of mutant SOD1 is observed in vivo, where the half-life of both G93A SOD1 
(Crisp et al 2015) and G85R SOD1 (Farr et al 2011) are accelerated compared to WT hSOD1 in 
transgenic animal models. Moreover, isolation of misfolded G93A SOD1 by 
immunoprecipitation with an antibody that specifically recognizes misfolded hSOD1 revealed 
that misfolded SOD1 shows faster protein kinetics than the entire G93A SOD1 pool (Crisp et al 
2015). Faster protein turnover is also observed in other models of neurological disorders, as 
mutations in glial fibrillary acidic protein which cause similarly decrease the half-life of mutant 
protein compared to wild type in animal models of Alexander’s Disease (Moody et al 2017). 
Further, Sato and colleagues used the presence of mutant SOD1 protein in red blood cells as a 
marker for altered protein turnover, where fast SOD1 turnover by erythrocytes suggests very 
misfolded proteins will not be present in these cells (Sato et al 2005). Because SOD1 is a 
ubiquitously-expressed protein, isolation from blood limits the ability to specifically understand 
SOD1 protein behavior in the CNS. However, we previously observed that CSF SOD1 half-life 
is similar to SOD1 from the brain and spinal cord (Crisp et al 2015), suggesting that our stable 
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isotope labeling method to measure CSF protein half-life will be informative of SOD1 
biochemistry within the human CNS.  
 Identification of misfolded SOD1 protein in humans by protein turnover will be of great 
value to developing ALS biomarkers, as the amorphous structure of SOD1 aggregates 
(Matsumoto et al 2006; Matsumoto et al 2005) impedes the development of imaging tracers to 
visualize protein misfolding events in human CNS tissues. For example, efforts to develop 
positron emission tomography radiotracers that bind amyloid-β (Klunk et al 2004) and tau 
(Johnson et al 2016) protein aggregates in Alzheimer’s Disease have proven successful due to 
the β-sheet rich, amyloid structures formed by these proteins. Therefore, to confirm that 
alterations in SOD1 protein kinetics describes misfolded SOD1 protein, future work must 
continue to develop other biochemical assays that specifically identify misfolded, pathogenic 
SOD1. A newly emerging biochemical property of misfolded proteins that cause 
neurodegenerative diseases is the amplification of a protein aggregate by templated 
conformational changes, ie.) “seeding”, similar to prion diseases (Kaufman & Diamond 2013; 
Prusiner 1982). Multiple assays have been developed to identify pathogenic protein seeds for 
proteins such as tau (Holmes et al 2013), alpha synuclein (Groveman et al 2018), and huntingtin 
(Tan et al 2015) in both CNS tissue and CSF of AD, PD, and HD patients.  Despite the non-
amyloid structure of SOD1 aggregates, multiple research groups demonstrated the ability of 
recombinant and cellular/tissue derived mutant SOD1 to seed intracellular SOD1 and propagate 
extracellularly (Ayers et al 2014; Chia et al 2010; Munch et al 2011). Therefore, the 
development of an SOD1 seeding assay may overcome previous limitations of antibody capture-
based methods to identify misfolded SOD1 species, while helping to establish the relationship 
between CSF SOD1 turnover and protein misfolding.  
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Future studies must also aim to elucidate the biochemical composition of SOD1 in human 
CSF to understand the relationship of a CSF biomarker to protein misfolding in the CNS. 
Dimerization is a unique feature of SOD1 structure compared to other proteins that contribute to 
neurodegeneration, and has been studied extensively to understand mutant SOD1 toxicity. 
Thermodynamic analyses of recombinant SOD1 protein (Khare & Dokholyan 2006; Lindberg et 
al) and imaging of SOD1 aggregation in live cells (Kim et al 2014) suggest that dimer 
destabilization is the first step in the production of SOD1 monomers that are capable of 
misfolding and forming protein aggregates. These observations are further supported by our 
natural history data, as A4 SOD1 mutants (A4V, A4T), and C-terminal missense and truncation 
mutants (V148G, G141X) are found at the SOD1 dimerization interface (Keerthana & 
Kolandaivel 2015) and show fast mean disease durations of less than 2 years. Moreover, the 
strongest correlation of SOD1 biochemical parameters in vitro and ALS clinical phenotypes is 
rate of disease progression and aggregation propensity of mutant protein (Pratt et al 2014; 
Prudencio et al 2009; Wang et al 2008).   
An added layer of complexity presents itself when considering ALS
SOD1
, as three potential 
SOD1 dimer pairs are possible: WT-WT, WT-Mutant, and Mutant-Mutant. Both mutant 
homodimers and WT-mutant heterodimers are implicated in motor neuron toxicity. In a subset of 
transgenic models, multiple reports suggest that crossing mutant SOD1-expressing transgenic 
mice with WT hSOD1-expressing mice accelerates disease phenotypes (Deng et al 2006; Wang 
et al 2009). Similarly, Witan and colleagues created artificial heterodimer and homodimer 
constructs of mutant and WT SOD1 and showed WT-mutant heterodimers induce a more toxic 
phenotype than mutant-mutant homodimers in C. Elegans (Witan et al 2008). The process of 
heterodimerization also appears to correlate with SOD1
ALS
 disease progression, as Shi and 
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colleagues demonstrated faster disease progression in SOD1 mutants that have a more favorable 
Gibbs free energy association of heterodimerization between mutant and WT recombinant SOD1 
protein (Shi et al 2016).  
Despite these extensive characterizations in vitro or overexpression paradigms in vivo, there 
are relatively few analyses examining SOD1 monomer and dimer state in humans that validate 
the physiological relevance of these laboratory findings to human ALS. The mass spectrometry-
based methods I developed to quantify protein concentration and turnover of mutant and WT 
SOD1 protein in human CSF provide the foundation to investigate these questions in living ALS 
participants. Further technical developments of “Top-Down” analyses to examine intact protein 
(Padula et al 2017) should thus aim to establish a relationship between CSF SOD1 biochemical 
characteristics and ALS clinical phenotypes. Future experiments using induced pluripotent stem 
cell-derived motor neuron should also examine how these observations in human CSF relate to 
motor neuron toxicity. By using iPSC’s derived from SOD1 mutant carriers, one can also create 
isogenic WT SOD1 or mutant SOD1-expressing lines and compare the three cell lines to test 
hypotheses describing the role of mutant SOD1 protein stability, dimer stability, and the 
presence of WT SOD1 modulating motor neuron toxicity (Imamura et al 2017; Wainger et al 
2014).   
Multiple studies have suggested a relationship between mutant SOD1 stability and rate of 
disease progression after symptom onset, but no work has reported a correlation with age of 
disease onset. One possible hypothesis that explains these results is that changes in proteostasis 
associated with aging drive the rate of disease onset, as protein degradation rates decrease over 
time within cells (McShane et al 2016). Previous work supports this hypothesis in other 
neurodegenerative diseases, as Patterson and colleagues demonstrated a highly significant 
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correlation between age and slow amyloid-beta turnover rates, suggesting that slowing of 
amyloid-beta turnover increases the likelihood of protein misfolding that leads to deposition 
(Patterson et al 2015). Similarly, single cell analysis of motor neurons in culture suggests that 
slower turnover of proteins implicated in ALS correlates to a cell’s susceptibility to degeneration 
(Barmada et al 2014), and aging is one of the strongest risk factors for ALS (Niccoli et al 2017). 
SOD1 is degraded by the ubiquitin proteasome system and macroautophagy within cells (Kabuta 
et al 2006), two pathways that slow over time (Dhondt et al 2017), suggesting that age-dependent 
effects of SOD1 turnover in the CNS and CSF may be observed in ALS
SOD1
. Families that carry 
the A4V SOD1 mutation are an ideal population to investigate the association between aging, 
SOD1 turnover, and clinical phenotypes, as the mutation exhibits a high degree of disease 
penetrance, with a rapid disease progression after symptom onset with little variability between 
patients. To determine if these changes in SOD1 turnover relate to motor neuron degeneration 
during disease time course, additional analyses should examine changes in CSF SOD1 kinetics 
with prognostic biomarkers associated with neuronal death, such as neurofilament light chain in 
CSF or plasma (Bacioglu et al 2016; Gaiani et al 2017; Lu et al 2015) or p75 extracellular 
domain fragments found in patient urine (Shepheard et al 2017).  
Future investigation of the ALS
SOD1
 population will be critical to establish any 
relationship between SOD1 half-life measures and disease pathobiology, and will determine the 
feasibility of identifying misfolded WT SOD1 by kinetics-based measures in ALS patients that 
do not have SOD1 mutations. Without a basic understanding of mutant SOD1 protein behavior, 
any investigation into kinetics-based approaches to test the hypothesis of misfolded SOD1 in 
sporadic ALS without SOD1 mutations will be difficult to interpret. Although the identification 
of SOD1 involvement in sporadic ALS would have a significant impact on treatment strategies 
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for the entire ALS population, further investigation in ALS
SOD1
 may confirm that pathogenic 
mechanisms associated with SOD1 mutations are specific to this subpopulation. If the 
interpretation of changes in CSF SOD1 kinetics is ultimately specific to ALS
SOD1
, future efforts 
should aim to use similar approaches on other proteins implicated in disease to expand the scope 
of the relationship between protein turnover and ALS pathogenesis.  
Of particular interest is TDP-43, the protein found in insoluble aggregates of motor 
neurons in the remaining 98% of ALS patients that do not carry SOD1 mutations (Neumann et al 
2006). Stable isotope labeling with 
13
C6-Leucine to measure TDP-43 protein kinetics in CSF of 
ALS patients is theoretically feasible, and the recent identification of TDP-43 in exosomes 
derived from CSF suggests that a CNS-specific pool of TDP-43 can be analyzed to measure 
protein turnover (Feneberg et al 2018; Feneberg et al 2014). Similar experiments described 
previously for CSF SOD1 can be directly translated to studies of TDP-43 in ALS, as the two 
proteins share similar characteristics of misfolding such as the involvement of post-translational 
modifications (Fujishiro et al 2009; Igaz et al 2008), and prion-like propagation (Nonaka et al 
2013). Aggregates of TDP-43 and C-terminal fragments of TDP-43 also appear to form amyloid 
structures (Bigio et al ; Garnier et al 2017), opening the possibility for future development of an 
imaging agent to observe TDP-43 aggregates in living ALS patients. Combining our SILK 
analysis with imaging would be invaluable to understand the relationship between CSF protein 
biomarkers and disease progression in the brain and spinal cord of ALS patients, as CSF protein 
biomarkers may provide a great cost effectiveness to implement in in the clinic compared to high 
costs associated with PET imaging scans (Mitka). In sum, future investigations of CSF protein 
kinetics should aim to identify a mechanistic link between protein homeostasis and 
neurodegeneration to better understand disease biology. Such findings would be crucial to help 
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understand the variability in prognosis and clinical phenotypes in ALS, with the hopes of leading 
to improved patient outcomes. Further, as new therapeutic candidates emerge that correct TDP-
43 pathology (Becker et al 2017), an understanding of TDP-43 turnover in the CNS will be 
needed.  
New Protein Production is a viable biomarker for RNA-lowering therapies  
 Understanding of protein turnover has direct application for experimental therapies under 
investigation for the treatment of ALS. In Chapter 4, I described how measurements of new 
protein production using 
13
C6-Leucine labeling serves as a pharmacodynamics assay to 
determine target engagement after therapeutic treatment. The primary focus of 
pharmacodynamics measures for ASOs in neurodegenerative diseases is target protein 
concentration in cerebrospinal fluid, confirmed by results in preclinical disease models that 
suggest changes in CNS protein levels are reflected in CSF (DeVos et al 2017; McCampbell et al 
2018). Excitingly, we observed changes in newly produced protein at earlier time points than 
protein concentration in both the CNS and CSF after ASO treatment (Figures 4.1, 4.2), 
suggesting that measures of newly produced protein are more sensitive measures of target 
engagement for treatments that inhibit protein synthesis. As stable isotope labeling is safe in 
humans (Crisp et al 2015; Ovod et al 2017; Sato et al 2018), measures of new protein production 
to determine drug target engagement are directly translatable to randomized control trials with 
drugs that inhibit SOD1 synthesis (Thomsen et al 2014) or promote protein clearance (Kieran et 
al 2004). As SOD1 ASO treatment is currently in clinical trials and using CSF SOD1 protein 
concentration as a secondary outcome (NCT02623699), our measures of new protein production 
can also be implemented into future studies. As most previous multicenter randomized control 
trials in ALS have failed to analyze any pharmacodynamics biomarkers (Mitsumoto et al 2014), 
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our results open a new opportunity to use protein kinetics to better understand the effects of 
experimental drugs on human ALS biology.     
Protein Turnover as a measure of pharmacodynamics for SOD1-targeting therapies 
 My research specifically focused on new protein production using stable isotope labeling 
with 
13
C6-Leucine, but measures of protein turnover and half-life also have potential utility as 
pharmacodynamics biomarkers. For example, an emerging class of drugs targets the proper 
folding and maturation of SOD1 to prevent mutant SOD1 toxicity. In a chaperone-mediated 
strategy, Das and colleagues developed a small molecule that inhibits protein phosphatase 1 to 
increase the availability of chaperones to bind to misfolded SOD1. Treatment with this molecule 
lowered misfolded SOD1 protein levels without changing total SOD1 protein concentration in 
G93A SOD1 transgenic mice, preventing motor neuron loss and rescuing motor deficits (Das et 
al 2015). Nagy and colleagues showed similar results through genetic overexpression of HSP110 
in mutant SOD1 transgenic animals (Nagy et al 2016). In an alternative approach, Capper and 
colleagues recently described a cysteine-reactive small molecule that promotes dimerization of 
SOD1 protein, restoring the monomer-dimer equilibrium of A4V SOD1 to wild-type in cell 
culture (Capper et al 2018). These data suggest that measures of protein concentration will not 
serve as a successful pharmacodynamics biomarker. However, stabilizing mutant SOD1 protein 
may lead to alterations in protein turnover, suggesting that half-life measurements of mutant 
SOD1 protein after treatment may be a viable biomarker. These hypotheses can be directly tested 
in vivo using our current labeling methods in preclinical models and humans, but also have the 
utility to be used as an assay to screen compounds that target proteostasis in neuronal cell culture 
(Sato et al 2018; Zhang et al 2014). To ultimately serve as a pharmacodynamics biomarker, it is 
imperative to determine the effect that such treatments will have on CSF SOD1. Such findings 
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have utility to both identify better measures of drug mechanism of action, but also our 
understanding of the biology underlying SOD1 release from cells into CSF.            
Understanding the mechanisms of CNS protein deposition into the CSF  
 Despite significant progress in our understanding of the correlations between CNS and 
CSF protein behavior, the mechanisms that govern SOD1 protein release into the extracellular 
space remain poorly understood. Traditionally thought to be a passive process associated with 
motor neuron degeneration, emerging evidence suggests that human cells secrete misfolded 
proteins through an active process (Fontaine et al 2016; Lee et al 2016a). Multiple groups 
reported unconventional secretion of mutant SOD1 in lower-order organisms such as yeast 
(Cruz-Garcia et al 2017) and human neurons through interaction with neurosecretory vesicles 
(Urushitani et al 2006). An additional factor implicated in extracellular release of proteins is 
neuronal activity, as increased neuronal activity leads to elevated levels of both amyloid beta 
(Cirrito et al 2003) and tau (Yamada et al 2014). Evidence suggests mutant SOD1-expressing 
neurons exhibit a hyperexcitability phenotype, so neuronal activity in the brain and spinal cord 
may influence extracellular release of SOD1 (Wainger et al 2014). Although previous data has 
primarily focused on neuronal release of misfolded proteins, it is also unknown how each cell 
type of the brain contributes to the pool of SOD1 found in CSF. Experiments in both transgenic 
animal models and motor neuron cell cultures can contribute to characterizing changes in SOD1 
turnover and extracellular release over time and through disease time course.  Excitingly, new 
drug candidates that target proper SOD1 folding and maturation provide an opportunity to 
provide a more complete picture on the role of SOD1 protein turnover affecting the behavior of 
CSF SOD1 protein by measures of protein concentration and half-life in vivo.  
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 Similarly, no studies have examined the clearance of either mutant or WT SOD1 protein 
from CSF. The identification of paravascular and dural lymphatic vascular systems that drive 
interstitial fluid and CSF flow (Aspelund et al 2015; Iliff et al 2012) present exciting 
opportunities to determine how the clearance of SOD1 protein influences measures of CSF 
SOD1 protein half-life. Within both vascular systems, the clearance of small fluorescent tracers 
and soluble amyloid beta peptide from CSF required specific receptors such as Aquaporin 4 and 
Vascular Endothelial Growth Factor Receptor. The molecular weight of SOD1 dimers (32 kDA) 
is similar to the size of fluorescent tracers used in these studies, suggesting experiments 
examining tagged SOD1 clearance from CSF are feasible to test hypotheses related to similar 
ligand-receptor relationships for the clearance of SOD1 protein in animal model systems. 
Therefore, future endeavors into understanding the mechanisms that drive SOD1 entrance and 
clearance from CSF will further advance our understanding of CSF protein biology and its utility 
as a biomarker in disease states.            
Concluding Remarks 
 The original report of ASOs targeting SOD1 in ALS was released over 10 years ago 
(Smith et al 2006), pioneering the use of RNA-lowering therapies for diseases of the CNS. The 
recent approval of ASOs that modulate splicing in juvenile-onset spinal muscular atrophy (Finkel 
et al 2017) pave the way for potential of RNA-lowering therapies for progressive 
neurodegenerative diseases to be realized in the near future. However, multiple challenges will 
persist as these promising therapeutic candidates advance through the clinic, and the SOD1 ASO 
randomized control trials will define the ability of the neurology field to learn from past failures 
in clinical trial design. In this dissertation, I provided new insights into ALS
SOD1
 epidemiology, 
CSF SOD1 protein behavior, and pharmacodynamics biomarker development to hopefully lead 
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to successful approval of ASO treatment in ALS
SOD1
. These challenges, among others, will 
continue to present themselves in the development of RNA-targeted therapies for other types of 
ALS, Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, Charcot-Marie Tooth 
Disease (Zhao et al 2018), as well as future disorders with yet to be defined targets. In sum, I 
hope the work described in this dissertation provides the foundation for future investigators in 
disease research, where experiments in the laboratory and clinic combine to reveal breakthroughs 
that ultimately lead to improvements in our understanding of human biology to combat and one 
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